ID   A4_HUMAN                Reviewed;         770 AA.
AC   P05067; B2R5V1; B4DII8; D3DSD1; D3DSD2; D3DSD3; P09000; P78438;
AC   Q13764; Q13778; Q13793; Q16011; Q16014; Q16019; Q16020; Q6GSC0;
AC   Q8WZ99; Q9BT38; Q9UC33; Q9UCA9; Q9UCB6; Q9UCC8; Q9UCD1; Q9UQ58;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 3.
DT   13-FEB-2019, entry version 280.
DE   RecName: Full=Amyloid-beta precursor protein {ECO:0000305};
DE            Short=APP {ECO:0000305};
DE   AltName: Full=ABPP;
DE   AltName: Full=APPI;
DE   AltName: Full=Alzheimer disease amyloid protein;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Amyloid-beta A4 protein;
DE   AltName: Full=Cerebral vascular amyloid peptide;
DE            Short=CVAP;
DE   AltName: Full=PreA4;
DE   AltName: Full=Protease nexin-II;
DE            Short=PN-II;
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha {ECO:0000303|PubMed:10656250};
DE              Short=S-APP-alpha {ECO:0000303|PubMed:10656250};
DE   Contains:
DE     RecName: Full=Soluble APP-beta {ECO:0000303|PubMed:10656250};
DE              Short=S-APP-beta {ECO:0000303|PubMed:10656250};
DE   Contains:
DE     RecName: Full=C99;
DE     AltName: Full=Beta-secretase C-terminal fragment {ECO:0000303|PubMed:10656250};
DE              Short=Beta-CTF {ECO:0000303|PubMed:10656250};
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 42 {ECO:0000303|PubMed:8886002};
DE              Short=Abeta42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 40 {ECO:0000303|PubMed:8886002};
DE              Short=Abeta40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE     AltName: Full=Alpha-secretase C-terminal fragment {ECO:0000303|PubMed:10656250};
DE              Short=Alpha-CTF {ECO:0000303|PubMed:10656250};
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=Amyloid intracellular domain 59;
DE              Short=AICD-59;
DE              Short=AID(59);
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=Amyloid intracellular domain 57;
DE              Short=AICD-57;
DE              Short=AID(57);
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Amyloid intracellular domain 50;
DE              Short=AICD-50;
DE              Short=AID(50);
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=APP {ECO:0000312|HGNC:HGNC:620}; Synonyms=A4, AD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=2881207; DOI=10.1038/325733a0;
RA   Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L.,
RA   Grzeschik K.-H., Multhaup G., Beyreuther K., Mueller-Hill B.;
RT   "The precursor of Alzheimer's disease amyloid A4 protein resembles a
RT   cell-surface receptor.";
RL   Nature 325:733-736(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2893289; DOI=10.1038/331525a0;
RA   Ponte P., Gonzalez-Dewhitt P., Schilling J., Miller J., Hsu D.,
RA   Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F.,
RA   Cordell B.;
RT   "A new A4 amyloid mRNA contains a domain homologous to serine
RT   proteinase inhibitors.";
RL   Nature 331:525-527(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP695).
RX   PubMed=2783775; DOI=10.1093/nar/17.2.517;
RA   Lemaire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,
RA   Unterbeck A., Beyreuther K., Mueller-Hill B.;
RT   "The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is
RT   encoded by 16 exons.";
RL   Nucleic Acids Res. 17:517-522(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=2110105; DOI=10.1016/0378-1119(90)90310-N;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RT   "Genomic organization of the human amyloid beta-protein precursor
RT   gene.";
RL   Gene 87:257-263(1990).
RN   [5]
RP   ERRATUM.
RX   PubMed=1908403; DOI=10.1016/0378-1119(91)90093-Q;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RL   Gene 102:291-292(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-APP733).
RC   TISSUE=Leukocyte;
RX   PubMed=1587857;
RA   Koenig G., Moenning U., Czech C., Prior R., Banati R.,
RA   Schreiter-Gasser U., Bauer J., Masters C.L., Beyreuther K.;
RT   "Identification and differential expression of a novel alternative
RT   splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in
RT   leukocytes and brain microglial cells.";
RL   J. Biol. Chem. 267:10804-10809(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=9108164; DOI=10.1093/nar/25.9.1802;
RA   Hattori M., Tsukahara F., Furuhata Y., Tanahashi H., Hirose M.,
RA   Saito M., Tsukuni S., Sakaki Y.;
RT   "A novel method for making nested deletions and its application for
RT   sequencing of a 300 kb region of human APP locus.";
RL   Nucleic Acids Res. 25:1802-1808(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP639), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=12859342; DOI=10.1046/j.1460-9568.2003.02731.x;
RA   Tang K., Wang C., Shen C., Sheng S., Ravid R., Jing N.;
RT   "Identification of a novel alternative splicing isoform of human
RT   amyloid precursor protein gene, APP639.";
RL   Eur. J. Neurosci. 18:102-108(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP770 AND 11).
RC   TISSUE=Cerebellum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-501.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP305 AND APP751).
RC   TISSUE=Eye, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-10.
RC   TISSUE=Liver;
RX   PubMed=3140222; DOI=10.1093/nar/16.19.9351;
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RT   "A cDNA specifying the human amyloid beta precursor protein (ABPP)
RT   encodes a 95-kDa polypeptide.";
RL   Nucleic Acids Res. 16:9351-9351(1988).
RN   [15]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RL   Nucleic Acids Res. 16:11402-11402(1988).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-75.
RX   PubMed=2538123; DOI=10.1016/0006-291X(89)92437-6;
RA   La Fauci G., Lahiri D.K., Salton S.R., Robakis N.K.;
RT   "Characterization of the 5'-end region and the first two exons of the
RT   beta-protein precursor gene.";
RL   Biochem. Biophys. Res. Commun. 159:297-304(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 18-50.
RC   TISSUE=Fibroblast;
RX   PubMed=3597385;
RA   van Nostrand W.E., Cunningham D.D.;
RT   "Purification of protease nexin II from human fibroblasts.";
RL   J. Biol. Chem. 262:8508-8514(1987).
RN   [18]
RP   PROTEIN SEQUENCE OF 18-40.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 286-366.
RX   PubMed=2893290; DOI=10.1038/331528a0;
RA   Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L.,
RA   Gusella J.F., Neve R.L.;
RT   "Protease inhibitor domain encoded by an amyloid protein precursor
RT   mRNA associated with Alzheimer's disease.";
RL   Nature 331:528-530(1988).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 287-367.
RX   PubMed=2893291; DOI=10.1038/331530a0;
RA   Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H.;
RT   "Novel precursor of Alzheimer's disease amyloid protein shows protease
RT   inhibitory activity.";
RL   Nature 331:530-532(1988).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 507-770.
RC   TISSUE=Brain cortex;
RX   PubMed=2893379; DOI=10.1073/pnas.85.3.929;
RA   Zain S.B., Salim M., Chou W.G., Sajdel-Sulkowska E.M., Majocha R.E.,
RA   Marotta C.A.;
RT   "Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer
RT   disease brain: coding and noncoding regions of the fetal precursor
RT   mRNA are expressed in the cortex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:929-933(1988).
RN   [22]
RP   PROTEIN SEQUENCE OF 523-555, AND DOMAIN COLLAGEN-BINDING.
RX   PubMed=8576160; DOI=10.1074/jbc.271.3.1613;
RA   Beher D., Hesse L., Masters C.L., Multhaup G.;
RT   "Regulation of amyloid protein precursor (APP) binding to collagen and
RT   mapping of the binding sites on APP and collagen type I.";
RL   J. Biol. Chem. 271:1613-1620(1996).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 655-737, AND VARIANTS AD1 GLY-717;
RP   ILE-717 AND PHE-717.
RX   PubMed=8476439; DOI=10.1006/bbrc.1993.1386;
RA   Denman R.B., Rosenzcwaig R., Miller D.L.;
RT   "A system for studying the effect(s) of familial Alzheimer disease
RT   mutations on the processing of the beta-amyloid peptide precursor.";
RL   Biochem. Biophys. Res. Commun. 192:96-103(1993).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.
RX   PubMed=2675837; DOI=10.1016/0006-291X(89)91112-1;
RA   Johnstone E.M., Chaney M.O., Moore R.E., Ward K.E., Norris F.H.,
RA   Little S.P.;
RT   "Alzheimer's disease amyloid peptide is encoded by two exons and shows
RT   similarity to soybean trypsin inhibitor.";
RL   Biochem. Biophys. Res. Commun. 163:1248-1255(1989).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 672-723, AND VARIANT AD1 ASN-678.
RX   PubMed=15201367; DOI=10.1136/jnnp.2003.010611;
RA   Wakutani Y., Watanabe K., Adachi Y., Wada-Isoe K., Urakami K.,
RA   Ninomiya H., Saido T.C., Hashimoto T., Iwatsubo T., Nakashima K.;
RT   "Novel amyloid precursor protein gene missense mutation (D678N) in
RT   probable familial Alzheimer's disease.";
RL   J. Neurol. Neurosurg. Psych. 75:1039-1042(2004).
RN   [26]
RP   PROTEIN SEQUENCE OF 672-681.
RC   TISSUE=Brain cortex;
RX   PubMed=3312495; DOI=10.1111/j.1471-4159.1987.tb01005.x;
RA   Pardridge W.M., Vinters H.V., Yang J., Eisenberg J., Choi T.B.,
RA   Tourtellotte W.W., Huebner V., Shively J.E.;
RT   "Amyloid angiopathy of Alzheimer's disease: amino acid composition and
RT   partial sequence of a 4,200-dalton peptide isolated from cortical
RT   microvessels.";
RL   J. Neurochem. 49:1394-1401(1987).
RN   [27]
RP   PROTEIN SEQUENCE OF 672-704, AND TISSUE SPECIFICITY.
RX   PubMed=1406936; DOI=10.1038/359325a0;
RA   Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA   Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT   "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT   biological fluids.";
RL   Nature 359:325-327(1992).
RN   [28]
RP   PROTEIN SEQUENCE OF 672-701.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=8229004; DOI=10.1111/j.1471-4159.1993.tb09841.x;
RA   Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D.B.;
RT   "Characterization of beta-amyloid peptide from human cerebrospinal
RT   fluid.";
RL   J. Neurochem. 61:1965-1968(1993).
RN   [29]
RP   PROTEIN SEQUENCE OF 672-713.
RC   TISSUE=Blood vessel;
RX   PubMed=8248178; DOI=10.1073/pnas.90.22.10836;
RA   Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J.,
RA   Gowing E., Ball M.J.;
RT   "Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid
RT   deposits: implications for the pathology of Alzheimer disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10836-10840(1993).
RN   [30]
RP   PROTEIN SEQUENCE OF 672-701 AND 707-713.
RX   PubMed=8109908; DOI=10.1002/ana.410350223;
RA   Wisniewski T., Lalowski M., Levy E., Marques M.R.F., Frangione B.;
RT   "The amino acid sequence of neuritic plaque amyloid from a familial
RT   Alzheimer's disease patient.";
RL   Ann. Neurol. 35:245-246(1994).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-770.
RC   TISSUE=Brain;
RX   PubMed=3810169; DOI=10.1126/science.3810169;
RA   Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C.;
RT   "Characterization and chromosomal localization of a cDNA encoding
RT   brain amyloid of Alzheimer's disease.";
RL   Science 235:877-880(1987).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-703.
RC   TISSUE=Fetal brain;
RX   PubMed=2949367; DOI=10.1126/science.2949367;
RA   Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.,
RA   St George-Hyslop P.H., Van Keuren M.L., Patterson D., Pagan S.,
RA   Kurnit D.M., Neve R.L.;
RT   "Amyloid beta protein gene: cDNA, mRNA distribution, and genetic
RT   linkage near the Alzheimer locus.";
RL   Science 235:880-884(1987).
RN   [33]
RP   PROTEIN SEQUENCE OF 609-713, AND GLYCOSYLATION AT THR-633; THR-651;
RP   THR-652; THR-659; THR-663; SER-667 AND TYR-681.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=22576872; DOI=10.1002/jms.2987;
RA   Brinkmalm G., Portelius E., Ohrfelt A., Mattsson N., Persson R.,
RA   Gustavsson M.K., Vite C.H., Gobom J., Mansson J.E., Nilsson J.,
RA   Halim A., Larson G., Ruetschi U., Zetterberg H., Blennow K.,
RA   Brinkmalm A.;
RT   "An online nano-LC-ESI-FTICR-MS method for comprehensive
RT   characterization of endogenous fragments from amyloid beta and amyloid
RT   precursor protein in human and cat cerebrospinal fluid.";
RL   J. Mass Spectrom. 47:591-603(2012).
RN   [34]
RP   PROTEIN SEQUENCE OF 691-698, AND PROTEOLYTIC CLEAVAGE AT PHE-690 BY
RP   THETA-SECRETASE.
RX   PubMed=16816112; DOI=10.1096/fj.05-5632com;
RA   Sun X., He G., Song W.;
RT   "BACE2, as a novel APP theta-secretase, is not responsible for the
RT   pathogenesis of Alzheimer's disease in Down syndrome.";
RL   FASEB J. 20:1369-1376(2006).
RN   [35]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2569763; DOI=10.1126/science.2569763;
RA   de Sauvage F., Octave J.-N.;
RT   "A novel mRNA of the A4 amyloid precursor gene coding for a possibly
RT   secreted protein.";
RL   Science 245:651-653(1989).
RN   [36]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=3035574; DOI=10.1073/pnas.84.12.4190;
RA   Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M.;
RT   "Molecular cloning and characterization of a cDNA encoding the
RT   cerebrovascular and the neuritic plaque amyloid peptides.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4190-4194(1987).
RN   [37]
RP   SUBCELLULAR LOCATION, SIGNAL SEQUENCE CLEAVAGE SITE, AND TOPOLOGY.
RX   PubMed=2900137;
RA   Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.-G.,
RA   Kang J., Mueller-Hill B., Masters C.L., Beyreuther K.;
RT   "Identification, transmembrane orientation and biogenesis of the
RT   amyloid A4 precursor of Alzheimer's disease.";
RL   EMBO J. 7:949-957(1988).
RN   [38]
RP   IDENTITY OF APP WITH NEXIN-II.
RX   PubMed=2506449; DOI=10.1038/341144a0;
RA   Oltersdorf T., Fritz L.C., Schenk D.B., Lieberburg I.,
RA   Johnson-Wood K.L., Beattie E.C., Ward P.J., Blacher R.W., Dovey H.F.,
RA   Sinha S.;
RT   "The secreted form of the Alzheimer's amyloid precursor protein with
RT   the Kunitz domain is protease nexin-II.";
RL   Nature 341:144-147(1989).
RN   [39]
RP   PROTEASE-SPECIFICITY OF INHIBITOR DOMAIN.
RX   PubMed=1969731; DOI=10.1016/0006-291X(90)92084-D;
RA   Kido H., Fukutomi A., Schilling J., Wang Y., Cordell B., Katunuma N.;
RT   "Protease-specificity of Kunitz inhibitor domain of Alzheimer's
RT   disease amyloid protein precursor.";
RL   Biochem. Biophys. Res. Commun. 167:716-721(1990).
RN   [40]
RP   EXTRACELLULAR ZINC-BINDING DOMAIN.
RX   PubMed=8344894;
RA   Bush A.I., Multhaup G., Moir R.D., Williamson T.G., Small D.H.,
RA   Rumble B., Pollwein P., Beyreuther K., Masters C.L.;
RT   "A novel zinc(II) binding site modulates the function of the beta A4
RT   amyloid protein precursor of Alzheimer's disease.";
RL   J. Biol. Chem. 268:16109-16112(1993).
RN   [41]
RP   INTERACTION WITH G(O).
RX   PubMed=8446172; DOI=10.1038/362075a0;
RA   Nishimoto I., Okamoto T., Matsuura Y., Takahashi S., Okamoto T.,
RA   Murayama Y., Ogata E.;
RT   "Alzheimer amyloid protein precursor complexes with brain GTP-binding
RT   protein G(o).";
RL   Nature 362:75-79(1993).
RN   [42]
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=8131745;
RA   Suzuki T., Oishi M., Marshak D.R., Czernik A.J., Nairn A.C.,
RA   Greengard P.;
RT   "Cell cycle-dependent regulation of the phosphorylation and metabolism
RT   of the Alzheimer amyloid precursor protein.";
RL   EMBO J. 13:1114-1122(1994).
RN   [43]
RP   EXTRACELLULAR COPPER-BINDING DOMAIN, AND MUTAGENESIS OF HIS-137;
RP   MET-141; CYS-144; HIS-147 AND HIS-151.
RX   PubMed=7913895; DOI=10.1016/0014-5793(94)00658-X;
RA   Hesse L., Beher D., Masters C.L., Multhaup G.;
RT   "The beta A4 amyloid precursor protein binding to copper.";
RL   FEBS Lett. 349:109-116(1994).
RN   [44]
RP   N-TERMINAL HEPARIN-BINDING DOMAIN, AND MUTAGENESIS OF 99-LYS--ARG-102.
RX   PubMed=8158260;
RA   Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K.,
RA   Masters C.L.;
RT   "A heparin-binding domain in the amyloid protein precursor of
RT   Alzheimer's disease is involved in the regulation of neurite
RT   outgrowth.";
RL   J. Neurosci. 14:2117-2127(1994).
RN   [45]
RP   CHARACTERIZATION OF L-APP733, AND MUTAGENESIS OF SER-656.
RX   PubMed=7737970; DOI=10.1074/jbc.270.18.10388;
RA   Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
RT   "The chondroitin sulfate attachment site of appican is formed by
RT   splicing out exon 15 of the amyloid precursor gene.";
RL   J. Biol. Chem. 270:10388-10391(1995).
RN   [46]
RP   INTERACTION WITH APP-BP1.
RX   PubMed=8626687; DOI=10.1074/jbc.271.19.11339;
RA   Chow N., Korenberg J.R., Chen X.-N., Neve R.L.;
RT   "APP-BP1, a novel protein that binds to the carboxyl-terminal region
RT   of the amyloid precursor protein.";
RL   J. Biol. Chem. 271:11339-11346(1996).
RN   [47]
RP   INTERACTION WITH APBA1 AND APBB1, AND MUTAGENESIS OF TYR-728; TYR-757;
RP   ASN-759 AND TYR-762.
RX   PubMed=8887653; DOI=10.1128/MCB.16.11.6229;
RA   Borg J.-P., Ooi J., Levy E., Margolis B.;
RT   "The phosphotyrosine interaction domains of X11 and FE65 bind to
RT   distinct sites on the YENPTY motif of amyloid precursor protein.";
RL   Mol. Cell. Biol. 16:6229-6241(1996).
RN   [48]
RP   INTERACTION WITH APBB2.
RX   PubMed=8855266; DOI=10.1073/pnas.93.20.10832;
RA   Guenette S.Y., Chen J., Jondro P.D., Tanzi R.E.;
RT   "Association of a novel human FE65-like protein with the cytoplasmic
RT   domain of the amyloid-beta precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10832-10837(1996).
RN   [49]
RP   FUNCTION OF AMYLOID-BETA PEPTIDE AS LIPID PEROXIDATION INHIBITOR, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=9168929; DOI=10.1006/bbrc.1997.6547;
RA   Walter M.F., Mason P.E., Mason R.P.;
RT   "Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid
RT   peroxidation as a result of its membrane interactions.";
RL   Biochem. Biophys. Res. Commun. 233:760-764(1997).
RN   [50]
RP   HEPARIN-BINDING DOMAINS.
RX   PubMed=9357988; DOI=10.1016/S0014-5793(97)01146-0;
RA   Mok S.S., Sberna G., Heffernan D., Cappai R., Galatis D.,
RA   Clarris H.J., Sawyer W.H., Beyreuther K., Masters C.L., Small D.H.;
RT   "Expression and analysis of heparin-binding regions of the amyloid
RT   precursor protein of Alzheimer's disease.";
RL   FEBS Lett. 415:303-307(1997).
RN   [51]
RP   INTERACTION OF AMYLOID-BETA PEPTIDE WITH HADH2.
RC   TISSUE=Brain;
RX   PubMed=9338779; DOI=10.1038/39522;
RA   Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F.,
RA   Collinson K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S.,
RA   Roher A., Stern D.;
RT   "An intracellular protein that binds amyloid-beta peptide and mediates
RT   neurotoxicity in Alzheimer's disease.";
RL   Nature 389:689-695(1997).
RN   [52]
RP   COPPER-BINDING, AND DISULFIDE BOND FORMATION.
RX   PubMed=9585534; DOI=10.1021/bi980022m;
RA   Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Bill E.,
RA   Pipkorn R., Masters C.L., Beyreuther K.;
RT   "Copper-binding amyloid precursor protein undergoes a site-specific
RT   fragmentation in the reduction of hydrogen peroxide.";
RL   Biochemistry 37:7224-7230(1998).
RN   [53]
RP   INTERACTION WITH APPBP2, MUTAGENESIS OF TYR-728, AND DOMAIN.
RX   PubMed=9843960; DOI=10.1073/pnas.95.25.14745;
RA   Zheng P., Eastman J., Vande Pol S., Pimplikar S.W.;
RT   "PAT1, a microtubule-interacting protein, recognizes the basolateral
RT   sorting signal of amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14745-14750(1998).
RN   [54]
RP   AMYLOID-BETA ZINC-BINDING, AND MUTAGENESIS OF ARG-676; TYR-681 AND
RP   HIS-684.
RX   PubMed=10413512; DOI=10.1021/bi990205o;
RA   Liu S.T., Howlett G., Barrow C.J.;
RT   "Histidine-13 is a crucial residue in the zinc ion-induced aggregation
RT   of the A beta peptide of Alzheimer's disease.";
RL   Biochemistry 38:9373-9378(1999).
RN   [55]
RP   PROTEOLYTIC CLEAVAGE AT ASP-197; ASP-219 AND ASP-739 BY CASPASES, AND
RP   MUTAGENESIS OF ASP-739.
RX   PubMed=10319819; DOI=10.1016/S0092-8674(00)80748-5;
RA   Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y.,
RA   Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E.,
RA   Zheng H., van der Ploeg L.H.T., Ruffolo S.C., Thornberry N.A.,
RA   Xanthoudakis S., Zamboni R.J., Roy S., Nicholson D.W.;
RT   "Involvement of caspases in proteolytic cleavage of Alzheimer's
RT   amyloid-beta precursor protein and amyloidogenic A beta peptide
RT   formation.";
RL   Cell 97:395-406(1999).
RN   [56]
RP   IMPORTANCE OF MET-706 IN FREE RADICAL OXIDATIVE STRESS, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=10535332; DOI=10.1016/S0361-9230(99)00093-3;
RA   Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A.;
RT   "Methionine residue 35 is important in amyloid beta-peptide-associated
RT   free radical oxidative stress.";
RL   Brain Res. Bull. 50:133-141(1999).
RN   [57]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND MUTAGENESIS OF THR-743.
RX   PubMed=10341243;
RA   Ando K., Oishi M., Takeda S., Iijima K., Isohara T., Nairn A.C.,
RA   Kirino Y., Greengard P., Suzuki T.;
RT   "Role of phosphorylation of Alzheimer's amyloid precursor protein
RT   during neuronal differentiation.";
RL   J. Neurosci. 19:4421-4427(1999).
RN   [58]
RP   INTERACTION WITH APBA2.
RX   PubMed=9890987; DOI=10.1074/jbc.274.4.2243;
RA   Tomita S., Ozaki T., Taru H., Oguchi S., Takeda S., Yagi Y.,
RA   Sakiyama S., Kirino Y., Suzuki T.;
RT   "Interaction of a neuron-specific protein containing PDZ domains with
RT   Alzheimer's amyloid precursor protein.";
RL   J. Biol. Chem. 274:2243-2254(1999).
RN   [59]
RP   SUBCELLULAR LOCATION, ENDOCYTOSIS SIGNAL, AND MUTAGENESIS OF TYR-728;
RP   GLY-756; TYR-757; ASN-759; PRO-760 AND TYR-762.
RX   PubMed=10383380; DOI=10.1074/jbc.274.27.18851;
RA   Perez R.G., Soriano S., Hayes J.D., Ostaszewski B., Xia W.,
RA   Selkoe D.J., Chen X., Stokin G.B., Koo E.H.;
RT   "Mutagenesis identifies new signals for beta-amyloid precursor protein
RT   endocytosis, turnover, and the generation of secreted fragments,
RT   including Abeta42.";
RL   J. Biol. Chem. 274:18851-18856(1999).
RN   [60]
RP   IMPORTANCE OF CYS-144 IN COPPER REDUCTION, AND MUTAGENESIS OF CYS-144
RP   AND 147-HIS--HIS-149.
RX   PubMed=10461923; DOI=10.1046/j.1471-4159.1999.0731288.x;
RA   Ruiz F.H., Gonzalez M., Bodini M., Opazo C., Inestrosa N.C.;
RT   "Cysteine 144 is a key residue in the copper reduction by the beta-
RT   amyloid precursor protein.";
RL   J. Neurochem. 73:1288-1292(1999).
RN   [61]
RP   CLEAVAGE BY BACE1, SUBCELLULAR LOCATION (SOLUBLE APP-BETA), AND
RP   CHARACTERIZATION OF VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=10656250; DOI=10.1006/mcne.1999.0811;
RA   Hussain I., Powell D.J., Howlett D.R., Tew D.G., Meek T.D.,
RA   Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M.,
RA   Smith T.S., Simmons D.L., Walsh F.S., Dingwall C., Christie G.;
RT   "Identification of a novel aspartic proteinase (Asp 2) as beta-
RT   secretase.";
RL   Mol. Cell. Neurosci. 14:419-427(1999).
RN   [62]
RP   INTERACTION OF AMYLOID-BETA WITH APOE.
RX   PubMed=10816430; DOI=10.1042/bj3480359;
RA   Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B.,
RA   Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., Frangione B.,
RA   Ghiso J.;
RT   "Lipidation of apolipoprotein E influences its isoform-specific
RT   interaction with Alzheimer's amyloid beta peptides.";
RL   Biochem. J. 348:359-365(2000).
RN   [63]
RP   INTERACTION OF APP42-BETA WITH CHRNA7.
RX   PubMed=10681545; DOI=10.1074/jbc.275.8.5626;
RA   Wang H.-Y., Lee D.H.S., D'Andrea M.R., Peterson P.A., Shank R.P.,
RA   Reitz A.B.;
RT   "Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor
RT   with high affinity. Implications for Alzheimer's disease pathology.";
RL   J. Biol. Chem. 275:5626-5632(2000).
RN   [64]
RP   IDENTIFICATION OF GAMMA-CTFS BY MASS SPECTROMETRY, MUTAGENESIS OF
RP   ASP-739, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=12214090;
RA   Passer B., Pellegrini L., Russo C., Siegel R.M., Lenardo M.J.,
RA   Schettini G., Bachmann M., Tabaton M., D'Adamio L.;
RT   "Generation of an apoptotic intracellular peptide by gamma-secretase
RT   cleavage of Alzheimer's amyloid beta protein precursor.";
RL   J. Alzheimers Dis. 2:289-301(2000).
RN   [65]
RP   REVIEW ON FUNCTION OF AMYLOID-BETA AS ANTIOXIDANT.
RX   PubMed=11775062; DOI=10.1023/A:1012629603390;
RA   Kontush A.;
RT   "Alzheimer's amyloid-beta as a preventive antioxidant for brain
RT   lipoproteins.";
RL   Cell. Mol. Neurobiol. 21:299-315(2001).
RN   [66]
RP   INTERACTION WITH FPR2 (AMYLOID-BETA PROTEIN 42), AND SUBCELLULAR
RP   LOCATION (AMYLOID-BETA PROTEIN 42).
RX   PubMed=11689470; DOI=10.1096/fj.01-0251com;
RA   Yazawa H., Yu Z.-X., Takeda K., Le Y., Gong W., Ferrans V.J.,
RA   Oppenheim J.J., Li C.C.H., Wang J.M.;
RT   "Beta amyloid peptide (Abeta42) is internalized via the G-protein-
RT   coupled receptor FPRL1 and forms fibrillar aggregates in
RT   macrophages.";
RL   FASEB J. 15:2454-2462(2001).
RN   [67]
RP   INTERACTION WITH BBP.
RX   PubMed=11278849; DOI=10.1074/jbc.M011161200;
RA   Kajkowski E.M., Lo C.F., Ning X., Walker S., Sofia H.J., Wang W.,
RA   Edris W., Chanda P., Wagner E., Vile S., Ryan K., McHendry-Rinde B.,
RA   Smith S.C., Wood A., Rhodes K.J., Kennedy J.D., Bard J.,
RA   Jacobsen J.S., Ozenberger B.A.;
RT   "Beta-amyloid peptide-induced apoptosis regulated by a novel protein
RT   containing a G protein activation module.";
RL   J. Biol. Chem. 276:18748-18756(2001).
RN   [68]
RP   AMYLOID-BETA COPPER AND ZINC-BINDING SITES.
RX   PubMed=11274207; DOI=10.1074/jbc.M100175200;
RA   Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S.,
RA   Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., Barnham K.J.;
RT   "Alzheimer's disease amyloid-beta binds copper and zinc to generate an
RT   allosterically ordered structure containing superoxide dismutase-like
RT   subunits.";
RL   J. Biol. Chem. 276:20466-20473(2001).
RN   [69]
RP   SUBUNIT.
RX   PubMed=11438549; DOI=10.1074/jbc.M105410200;
RA   Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D.,
RA   Bayer T.A., Beyreuther K., Multhaup G.;
RT   "Homodimerization of amyloid precursor protein and its implication in
RT   the amyloidogenic pathway of Alzheimer's disease.";
RL   J. Biol. Chem. 276:33923-33929(2001).
RN   [70]
RP   INTERACTION WITH APBB1, FUNCTION, AND SUBCELLULAR LOCATION
RP   (GAMMA-SECRETASE C-TERMINAL FRAGMENT 59).
RX   PubMed=11544248; DOI=10.1074/jbc.C100447200;
RA   Kimberly W.T., Zheng J.B., Guenette S.Y., Selkoe D.J.;
RT   "The intracellular domain of the beta-amyloid precursor protein is
RT   stabilized by Fe65 and translocates to the nucleus in a notch-like
RT   manner.";
RL   J. Biol. Chem. 276:40288-40292(2001).
RN   [71]
RP   INTERACTION WITH FBLN1.
RX   PubMed=11238726; DOI=10.1046/j.1471-4159.2001.00144.x;
RA   Ohsawa I., Takamura C., Kohsaka S.;
RT   "Fibulin-1 binds the amino-terminal head of beta-amyloid precursor
RT   protein and modulates its physiological function.";
RL   J. Neurochem. 76:1411-1420(2001).
RN   [72]
RP   INTERACTION WITH MAPT, AND FUNCTION.
RX   PubMed=11943163; DOI=10.1016/S0014-5793(02)02376-1;
RA   Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B.,
RA   Fleck T.J., Johnston J.A., Sharma S.K.;
RT   "Direct interaction of soluble human recombinant tau protein with
RT   Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau
RT   protein kinase II.";
RL   FEBS Lett. 514:263-268(2002).
RN   [73]
RP   INTERACTION WITH MAPK8IP1, AND MUTAGENESIS OF TYR-757.
RX   PubMed=11724784; DOI=10.1074/jbc.M108357200;
RA   Scheinfeld M.H., Roncarati R., Vito P., Lopez P.A., Abdallah M.,
RA   D'Adamio L.;
RT   "Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the
RT   cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein
RT   (APP).";
RL   J. Biol. Chem. 277:3767-3775(2002).
RN   [74]
RP   COPPER-MEDIATED LIPID PEROXIDATION, AND MUTAGENESIS OF HIS-147 AND
RP   HIS-151.
RX   PubMed=11784781;
RA   White A.R., Multhaup G., Galatis D., McKinstry W.J., Parker M.W.,
RA   Pipkorn R., Beyreuther K., Masters C.L., Cappai R.;
RT   "Contrasting species-dependent modulation of copper-mediated
RT   neurotoxicity by the Alzheimer's disease amyloid precursor protein.";
RL   J. Neurosci. 22:365-376(2002).
RN   [75]
RP   REVIEW ON ZINC-BINDING.
RX   PubMed=12032279; DOI=10.1073/pnas.122249699;
RA   Bush A.I., Tanzi R.E.;
RT   "The galvanization of beta-amyloid in Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7317-7319(2002).
RN   [76]
RP   PHOSPHORYLATION AT SER-198 AND SER-206 BY CASEIN KINASES, AND
RP   MUTAGENESIS OF SER-198 AND SER-206.
RX   PubMed=8999878; DOI=10.1074/jbc.272.3.1896;
RA   Walter J., Capell A., Hung A.Y., Langen H., Schnoelzer M.,
RA   Thinakaran G., Sisodia S.S., Selkoe D.J., Haass C.;
RT   "Ectodomain phosphorylation of beta-amyloid precursor protein at two
RT   distinct cellular locations.";
RL   J. Biol. Chem. 272:1896-1903(1997).
RN   [77]
RP   CHARACTERIZATION OF CASEIN KINASE PHOSPHORYLATION, AND MUTAGENESIS OF
RP   SER-198 AND SER-206.
RX   PubMed=10806211; DOI=10.1074/jbc.M002850200;
RA   Walter J., Schindzielorz A., Hartung B., Haass C.;
RT   "Phosphorylation of the beta-amyloid precursor protein at the cell
RT   surface by ectocasein kinases 1 and 2.";
RL   J. Biol. Chem. 275:23523-23529(2000).
RN   [78]
RP   PROTEOLYTIC CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.
RX   PubMed=10742146; DOI=10.1038/74656;
RA   Lu D.C., Rabizadeh S., Chandra S., Shayya R.F., Ellerby L.M., Ye X.,
RA   Salvesen G.S., Koo E.H., Bredesen D.E.;
RT   "A second cytotoxic proteolytic peptide derived from amyloid beta-
RT   protein precursor.";
RL   Nat. Med. 6:397-404(2000).
RN   [79]
RP   PHOSPHORYLATION, INTERACTION WITH APBB1, AND MUTAGENESIS OF THR-743.
RX   PubMed=11517218; DOI=10.1074/jbc.M104059200;
RA   Ando K., Iijima K., Elliott J.I., Kirino Y., Suzuki T.;
RT   "Phosphorylation-dependent regulation of the interaction of amyloid
RT   precursor protein with Fe65 affects the production of beta-amyloid.";
RL   J. Biol. Chem. 276:40353-40361(2001).
RN   [80]
RP   PHOSPHORYLATION BY MAPK10, AND MUTAGENESIS OF THR-743.
RX   PubMed=11146006; DOI=10.1046/j.1471-4159.2001.00102.x;
RA   Standen C.L., Brownlees J., Grierson A.J., Kesavapany S., Lau K.-F.,
RA   McLoughlin D.M., Miller C.C.J.;
RT   "Phosphorylation of thr(668) in the cytoplasmic domain of the
RT   Alzheimer's disease amyloid precursor protein by stress-activated
RT   protein kinase 1b (Jun N-terminal kinase-3).";
RL   J. Neurochem. 76:316-320(2001).
RN   [81]
RP   PROTEOLYTIC CLEAVAGE AT MET-671; LYS-687; VAL-711; ALA-713 AND
RP   LEU-720.
RX   PubMed=11851430; DOI=10.1021/bi015794o;
RA   Weidemann A., Eggert S., Reinhard F.B.M., Vogel M., Paliga K.,
RA   Baier G., Masters C.L., Beyreuther K., Evin G.;
RT   "A novel epsilon-cleavage within the transmembrane domain of the
RT   Alzheimer amyloid precursor protein demonstrates homology with Notch
RT   processing.";
RL   Biochemistry 41:2825-2835(2002).
RN   [82]
RP   PHOSPHORYLATION AT TYR-757, INTERACTION WITH SHC1, AND MUTAGENESIS OF
RP   THR-743 AND TYR-757.
RX   PubMed=11877420; DOI=10.1074/jbc.M110286200;
RA   Tarr P.E., Roncarati R., Pelicci G., Pelicci P.G., D'Adamio L.;
RT   "Tyrosine phosphorylation of the beta-amyloid precursor protein
RT   cytoplasmic tail promotes interaction with Shc.";
RL   J. Biol. Chem. 277:16798-16804(2002).
RN   [83]
RP   REVIEW.
RX   PubMed=12142279; DOI=10.1146/annurev.cellbio.18.020402.142302;
RA   Annaert W., De Strooper B.;
RT   "A cell biological perspective on Alzheimer's disease.";
RL   Annu. Rev. Cell Dev. Biol. 18:25-51(2002).
RN   [84]
RP   SUBCELLULAR LOCATION, AND ASSOCIATION OF AMYLOID FIBRILS WITH GCP1.
RX   PubMed=15084524; DOI=10.1096/fj.03-1040fje;
RA   Watanabe N., Araki W., Chui D.H., Makifuchi T., Ihara Y., Tabira T.;
RT   "Glypican-1 as an Abeta binding HSPG in the human brain: its
RT   localization in DIG domains and possible roles in the pathogenesis of
RT   Alzheimer's disease.";
RL   FASEB J. 18:1013-1015(2004).
RN   [85]
RP   INTERACTION WITH ANKS1B.
RX   PubMed=15347684; DOI=10.1074/jbc.M405329200;
RA   Ghersi E., Noviello C., D'Adamio L.;
RT   "Amyloid-beta protein precursor (AbetaPP) intracellular domain-
RT   associated protein-1 proteins bind to AbetaPP and modulate its
RT   processing in an isoform-specific manner.";
RL   J. Biol. Chem. 279:49105-49112(2004).
RN   [86]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-542.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [87]
RP   INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R.,
RA   Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X.,
RA   Bales K.R., Cappai R., Masters C.L., Gliemann J., Mufson E.J.,
RA   Hyman B.T., Paul S.M., Nykjaer A., Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates
RT   processing of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [88]
RP   INTERACTION WITH APBB1.
RX   PubMed=18468999; DOI=10.1074/jbc.M801827200;
RA   Nakaya T., Kawai T., Suzuki T.;
RT   "Regulation of FE65 nuclear translocation and function by amyloid
RT   beta-protein precursor in osmotically stressed cells.";
RL   J. Biol. Chem. 283:19119-19131(2008).
RN   [89]
RP   INTERACTION WITH ITM2C.
RX   PubMed=19366692; DOI=10.1074/jbc.M109.006403;
RA   Matsuda S., Matsuda Y., D'Adamio L.;
RT   "BRI3 inhibits amyloid precursor protein processing in a
RT   mechanistically distinct manner from its homologue dementia gene
RT   BRI2.";
RL   J. Biol. Chem. 284:15815-15825(2009).
RN   [90]
RP   FUNCTION, PROTEOLYTIC CLEAVAGE, AND INTERACTION WITH TNFRSF21.
RX   PubMed=19225519; DOI=10.1038/nature07767;
RA   Nikolaev A., McLaughlin T., O'Leary D.D.M., Tessier-Lavigne M.;
RT   "APP binds DR6 to trigger axon pruning and neuron death via distinct
RT   caspases.";
RL   Nature 457:981-989(2009).
RN   [91]
RP   FUNCTION, AND INTERACTION WITH AGER.
RX   PubMed=19901339; DOI=10.1073/pnas.0905686106;
RA   Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A.,
RA   McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D.,
RA   Hori O., Ogawa S., Stern D.M., Yamada K., Yan S.S.;
RT   "RAGE-mediated signaling contributes to intraneuronal transport of
RT   amyloid-{beta} and neuronal dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20021-20026(2009).
RN   [92]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20580937; DOI=10.1016/j.bbalip.2010.05.010;
RA   Cossec J.C., Simon A., Marquer C., Moldrich R.X., Leterrier C.,
RA   Rossier J., Duyckaerts C., Lenkei Z., Potier M.C.;
RT   "Clathrin-dependent APP endocytosis and Abeta secretion are highly
RT   sensitive to the level of plasma membrane cholesterol.";
RL   Biochim. Biophys. Acta 1801:846-852(2010).
RN   [93]
RP   INTERACTION WITH GSAP.
RX   PubMed=20811458; DOI=10.1038/nature09325;
RA   He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J.,
RA   Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., Greengard P.;
RT   "Gamma-secretase activating protein is a therapeutic target for
RT   Alzheimer's disease.";
RL   Nature 467:95-98(2010).
RN   [94]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [95]
RP   GLYCOSYLATION AT THR-633; THR-651; THR-652; SER-656; THR-663 AND
RP   SER-667 PROTEOLYTIC PROCESSING, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21712440; DOI=10.1073/pnas.1102664108;
RA   Halim A., Brinkmalm G., Ruetschi U., Westman-Brinkmalm A.,
RA   Portelius E., Zetterberg H., Blennow K., Larson G., Nilsson J.;
RT   "Site-specific characterization of threonine, serine, and tyrosine
RT   glycosylations of amyloid precursor protein/amyloid beta-peptides in
RT   human cerebrospinal fluid.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11848-11853(2011).
RN   [96]
RP   INTERACTION WITH S100A9.
RX   PubMed=22457725; DOI=10.1371/journal.pone.0032953;
RA   Zhang C., Liu Y., Gilthorpe J., van der Maarel J.R.;
RT   "MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide
RT   and induces its fibrillization.";
RL   PLoS ONE 7:E32953-E32953(2012).
RN   [97]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-743, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [98]
RP   INTERACTION WITH PLD3.
RX   PubMed=24336208; DOI=10.1038/nature12825;
RG   UK Brain Expression Consortium;
RA   Cruchaga C., Karch C.M., Jin S.C., Benitez B.A., Cai Y., Guerreiro R.,
RA   Harari O., Norton J., Budde J., Bertelsen S., Jeng A.T., Cooper B.,
RA   Skorupa T., Carrell D., Levitch D., Hsu S., Choi J., Ryten M.,
RA   Hardy J., Ryten M., Trabzuni D., Weale M.E., Ramasamy A., Smith C.,
RA   Sassi C., Bras J., Gibbs J.R., Hernandez D.G., Lupton M.K., Powell J.,
RA   Forabosco P., Ridge P.G., Corcoran C.D., Tschanz J.T., Norton M.C.,
RA   Munger R.G., Schmutz C., Leary M., Demirci F.Y., Bamne M.N., Wang X.,
RA   Lopez O.L., Ganguli M., Medway C., Turton J., Lord J., Braae A.,
RA   Barber I., Brown K., Passmore P., Craig D., Johnston J.,
RA   McGuinness B., Todd S., Heun R., Kolsch H., Kehoe P.G., Hooper N.M.,
RA   Vardy E.R., Mann D.M., Pickering-Brown S., Brown K., Kalsheker N.,
RA   Lowe J., Morgan K., David Smith A., Wilcock G., Warden D., Holmes C.,
RA   Pastor P., Lorenzo-Betancor O., Brkanac Z., Scott E., Topol E.,
RA   Morgan K., Rogaeva E., Singleton A.B., Hardy J., Kamboh M.I.,
RA   St George-Hyslop P., Cairns N., Morris J.C., Kauwe J.S., Goate A.M.;
RT   "Rare coding variants in the phospholipase D3 gene confer risk for
RT   Alzheimer's disease.";
RL   Nature 505:550-554(2014).
RN   [99]
RP   INTERACTION WITH VDAC1.
RX   PubMed=25168729; DOI=10.1016/j.neuroscience.2014.07.079;
RA   Fernandez-Echevarria C., Diaz M., Ferrer I., Canerina-Amaro A.,
RA   Marin R.;
RT   "Abeta promotes VDAC1 channel dephosphorylation in neuronal lipid
RT   rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's
RT   disease.";
RL   Neuroscience 278:354-366(2014).
RN   [100]
RP   PHOSPHORYLATION AT SER-441 AND TYR-497.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [101]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 287-344.
RX   PubMed=2125487; DOI=10.1021/bi00495a002;
RA   Hynes T.R., Randal M., Kennedy L.A., Eigenbrot C., Kossiakof A.A.;
RT   "X-ray crystal structure of the protease inhibitor domain of
RT   Alzheimer's amyloid beta-protein precursor.";
RL   Biochemistry 29:10018-10022(1990).
RN   [102]
RP   STRUCTURE BY NMR OF 289-344.
RX   PubMed=1718421; DOI=10.1021/bi00107a015;
RA   Heald S.L., Tilton R.F. Jr., Hammond L.S., Lee A., Bayney R.M.,
RA   Kamarck M.E., Ramabhadran T.V., Dreyer R.N., Davis G., Unterbeck A.,
RA   Tamburini P.P.;
RT   "Sequential NMR resonance assignment and structure determination of
RT   the Kunitz-type inhibitor domain of the Alzheimer's beta-amyloid
RT   precursor protein.";
RL   Biochemistry 30:10467-10478(1991).
RN   [103]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=7516706; DOI=10.1021/bi00191a006;
RA   Talafous J., Marcinowski K.J., Klopman G., Zagorski M.G.;
RT   "Solution structure of residues 1-28 of the amyloid beta-peptide.";
RL   Biochemistry 33:7788-7796(1994).
RN   [104]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=7588758; DOI=10.1111/j.1432-1033.1995.293_1.x;
RA   Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K.,
RA   Frank R.W., Rosch P.;
RT   "Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease.";
RL   Eur. J. Biochem. 233:293-298(1995).
RN   [105]
RP   STRUCTURE BY NMR OF 696-706.
RX   PubMed=8973180; DOI=10.1021/bi961598j;
RA   Kohno T., Kobayashi K., Maeda T., Sato K., Takashima A.;
RT   "Three-dimensional structures of the amyloid beta peptide (25-35) in
RT   membrane-mimicking environment.";
RL   Biochemistry 35:16094-16104(1996).
RN   [106]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF KUNITZ DOMAIN IN COMPLEX WITH
RP   CHYMOTRYPSIN; TRYPSIN AND BASIC PANCREATIC TRYPSIN INHIBITOR.
RX   PubMed=9300481; DOI=10.1002/pro.5560060902;
RA   Scheidig A.J., Hynes T.R., Pelletier L.A., Wells J.A.,
RA   Kossiakoff A.A.;
RT   "Crystal structures of bovine chymotrypsin and trypsin complexed to
RT   the inhibitor domain of Alzheimer's amyloid beta-protein precursor
RT   (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of
RT   inhibitors with altered specificities.";
RL   Protein Sci. 6:1806-1824(1997).
RN   [107]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=9693002; DOI=10.1021/bi972979f;
RA   Coles M., Bicknell W., Watson A.A., Fairlie D.P., Craik D.J.;
RT   "Solution structure of amyloid beta-peptide(1-40) in a water-micelle
RT   environment. Is the membrane-spanning domain where we think it is?";
RL   Biochemistry 37:11064-11077(1998).
RN   [108]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 28-123.
RX   PubMed=10201399; DOI=10.1038/7562;
RA   Rossjohn J., Cappai R., Feil S.C., Henry A., McKinstry W.J.,
RA   Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C.L.,
RA   Parker M.W.;
RT   "Crystal structure of the N-terminal, growth factor-like domain of
RT   Alzheimer amyloid precursor protein.";
RL   Nat. Struct. Biol. 6:327-331(1999).
RN   [109]
RP   STRUCTURE OF CAA-APP VARIANTS.
RX   PubMed=10821838; DOI=10.1074/jbc.M003154200;
RA   Miravalle L., Tokuda T., Chiarle R., Giaccone G., Bugiani O.,
RA   Tagliavini F., Frangione B., Ghiso J.;
RT   "Substitutions at codon 22 of Alzheimer's Abeta peptide induce diverse
RT   conformational changes and apoptotic effects in human cerebral
RT   endothelial cells.";
RL   J. Biol. Chem. 275:27110-27116(2000).
RN   [110]
RP   STRUCTURE BY NMR OF 681-706.
RX   PubMed=10940221; DOI=10.1006/jsbi.2000.4288;
RA   Zhang S., Iwata K., Lachenmann M.J., Peng J.W., Li S., Stimson E.R.,
RA   Lu Y., Felix A.M., Maggio J.E., Lee J.P.;
RT   "The Alzheimer's peptide a beta adopts a collapsed coil structure in
RT   water.";
RL   J. Struct. Biol. 130:130-141(2000).
RN   [111]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=10940222; DOI=10.1006/jsbi.2000.4267;
RA   Poulsen S.-A., Watson A.A., Craik D.J.;
RT   "Solution structures in aqueous SDS micelles of two amyloid beta
RT   peptides of Abeta(1-28) mutated at the alpha-secretase cleavage
RT   site.";
RL   J. Struct. Biol. 130:142-152(2000).
RN   [112] {ECO:0000244|PDB:1OWT}
RP   STRUCTURE BY NMR OF 124-189, DISULFIDE BONDS, AND COPPER-BINDING
RP   SITES.
RX   PubMed=12611883; DOI=10.1074/jbc.M300629200;
RA   Barnham K.J., McKinstry W.J., Multhaup G., Galatis D., Morton C.J.,
RA   Curtain C.C., Williamson N.A., White A.R., Hinds M.G., Norton R.S.,
RA   Beyreuther K., Masters C.L., Parker M.W., Cappai R.;
RT   "Structure of the Alzheimer's disease amyloid precursor protein copper
RT   binding domain. A regulator of neuronal copper homeostasis.";
RL   J. Biol. Chem. 278:17401-17407(2003).
RN   [113]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 346-551, PARTIAL PROTEIN
RP   SEQUENCE, MUTAGENESIS OF ARG-499 AND LYS-503, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=15304215; DOI=10.1016/j.molcel.2004.06.037;
RA   Wang Y., Ha Y.;
RT   "The X-ray structure of an antiparallel dimer of the human amyloid
RT   precursor protein E2 domain.";
RL   Mol. Cell 15:343-353(2004).
RN   [114]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-711 IN COMPLEX WITH IDE.
RX   PubMed=17051221; DOI=10.1038/nature05143;
RA   Shen Y., Joachimiak A., Rosner M.R., Tang W.-J.;
RT   "Structures of human insulin-degrading enzyme reveal a new substrate
RT   recognition mechanism.";
RL   Nature 443:870-874(2006).
RN   [115]
RP   X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 133-189, AND DISULFIDE
RP   BONDS.
RX   PubMed=17909280; DOI=10.1107/S1744309107041139;
RA   Kong G.K., Adams J.J., Cappai R., Parker M.W.;
RT   "Structure of Alzheimer's disease amyloid precursor protein copper-
RT   binding domain at atomic resolution.";
RL   Acta Crystallogr. F 63:819-824(2007).
RN   [116] {ECO:0000244|PDB:2FJZ, ECO:0000244|PDB:2FK1, ECO:0000244|PDB:2FK2, ECO:0000244|PDB:2FK3, ECO:0000244|PDB:2FKL}
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 133-189 IN COMPLEXES WITH
RP   COPPER IONS, AND DISULFIDE BONDS.
RX   PubMed=17239395; DOI=10.1016/j.jmb.2006.12.041;
RA   Kong G.K., Adams J.J., Harris H.H., Boas J.F., Curtain C.C.,
RA   Galatis D., Masters C.L., Barnham K.J., McKinstry W.J., Cappai R.,
RA   Parker M.W.;
RT   "Structural studies of the Alzheimer's amyloid precursor protein
RT   copper-binding domain reveal how it binds copper ions.";
RL   J. Mol. Biol. 367:148-161(2007).
RN   [117]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 672-679 IN COMPLEX WITH IGG.
RX   PubMed=17895381; DOI=10.1073/pnas.0705888104;
RA   Gardberg A.S., Dice L.T., Ou S., Rich R.L., Helmbrecht E., Ko J.,
RA   Wetzel R., Myszka D.G., Patterson P.H., Dealwis C.;
RT   "Molecular basis for passive immunotherapy of Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:15659-15664(2007).
RN   [118]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 672-678 IN COMPLEXES WITH
RP   ANTIBODY FAB FRAGMENTS.
RX   PubMed=19923222; DOI=10.1074/jbc.M109.045187;
RA   Basi G.S., Feinberg H., Oshidari F., Anderson J., Barbour R.,
RA   Baker J., Comery T.A., Diep L., Gill D., Johnson-Wood K., Goel A.,
RA   Grantcharova K., Lee M., Li J., Partridge A., Griswold-Prenner I.,
RA   Piot N., Walker D., Widom A., Pangalos M.N., Seubert P.,
RA   Jacobsen J.S., Schenk D., Weis W.I.;
RT   "Structural correlates of antibodies associated with acute reversal of
RT   amyloid beta-related behavioral deficits in a mouse model of Alzheimer
RT   disease.";
RL   J. Biol. Chem. 285:3417-3427(2010).
RN   [119]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 18-190, PARTIAL PROTEIN
RP   SEQUENCE, SUBUNIT, DISULFIDE BONDS, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20212142; DOI=10.1073/pnas.0911326107;
RA   Dahms S.O., Hoefgen S., Roeser D., Schlott B., Guhrs K.H., Than M.E.;
RT   "Structure and biochemical analysis of the heparin-induced E1 dimer of
RT   the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:5381-5386(2010).
RN   [120] {ECO:0000244|PDB:2LOH}
RP   STRUCTURE BY NMR OF 686-726, AND SUBCELLULAR LOCATION.
RX   PubMed=22584060; DOI=10.1016/j.febslet.2012.04.062;
RA   Nadezhdin K.D., Bocharova O.V., Bocharov E.V., Arseniev A.S.;
RT   "Dimeric structure of transmembrane domain of amyloid precursor
RT   protein in micellar environment.";
RL   FEBS Lett. 586:1687-1692(2012).
RN   [121] {ECO:0000244|PDB:2LP1}
RP   STRUCTURE BY NMR OF 671-770, AND SUBCELLULAR LOCATION.
RX   PubMed=22654059; DOI=10.1126/science.1219988;
RA   Barrett P.J., Song Y., Van Horn W.D., Hustedt E.J., Schafer J.M.,
RA   Hadziselimovic A., Beel A.J., Sanders C.R.;
RT   "The amyloid precursor protein has a flexible transmembrane domain and
RT   binds cholesterol.";
RL   Science 336:1168-1171(2012).
RN   [122] {ECO:0000244|PDB:4JFN}
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 23-185 IN COMPLEX WITH
RP   COPPER, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, DOMAIN, DISULFIDE
RP   BONDS, AND MUTAGENESIS OF HIS-108; HIS-110; HIS-147 AND HIS-151.
RX   PubMed=25122912; DOI=10.1523/JNEUROSCI.0180-14.2014;
RA   Baumkotter F., Schmidt N., Vargas C., Schilling S., Weber R.,
RA   Wagner K., Fiedler S., Klug W., Radzimanowski J., Nickolaus S.,
RA   Keller S., Eggert S., Wild K., Kins S.;
RT   "Amyloid precursor protein dimerization and synaptogenic function
RT   depend on copper binding to the growth factor-like domain.";
RL   J. Neurosci. 34:11159-11172(2014).
RN   [123] {ECO:0000244|PDB:2MGT}
RP   STRUCTURE BY NMR OF 672-687, ZINC-BINDING SITES, AND DOMAIN.
RX   PubMed=26898943; DOI=10.1038/srep21734;
RA   Istrate A.N., Kozin S.A., Zhokhov S.S., Mantsyzov A.B., Kechko O.I.,
RA   Pastore A., Makarov A.A., Polshakov V.I.;
RT   "Interplay of histidine residues of the Alzheimer's disease Abeta
RT   peptide governs its Zn-induced oligomerization.";
RL   Sci. Rep. 6:21734-21734(2016).
RN   [124] {ECO:0000244|PDB:5LFY}
RP   STRUCTURE BY NMR OF 672-681, AND DOMAIN.
RX   PubMed=28570778; DOI=10.1002/anie.201704615;
RA   Polshakov V.I., Mantsyzov A.B., Kozin S.A., Adzhubei A.A.,
RA   Zhokhov S.S., van Beek W., Kulikova A.A., Indeykina M.I.,
RA   Mitkevich V.A., Makarov A.A.;
RT   "A Binuclear Zinc Interaction Fold Discovered in the Homodimer of
RT   Alzheimer's Amyloid-beta Fragment with Taiwanese Mutation D7H.";
RL   Angew. Chem. Int. Ed. Engl. 56:11734-11739(2017).
RN   [125] {ECO:0000244|PDB:5OQV}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.00 ANGSTROMS) OF 672-713.
RX   PubMed=28882996; DOI=10.1126/science.aao2825;
RA   Gremer L., Scholzel D., Schenk C., Reinartz E., Labahn J.,
RA   Ravelli R.B.G., Tusche M., Lopez-Iglesias C., Hoyer W., Heise H.,
RA   Willbold D., Schroder G.F.;
RT   "Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy.";
RL   Science 358:116-119(2017).
RN   [126] {ECO:0000244|PDB:5VOS}
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.42 ANGSTROMS) OF 695-705.
RX   PubMed=29282295; DOI=10.1074/jbc.M117.806109;
RA   Krotee P., Griner S.L., Sawaya M.R., Cascio D., Rodriguez J.A.,
RA   Shi D., Philipp S., Murray K., Saelices L., Lee J., Seidler P.,
RA   Glabe C.G., Jiang L., Gonen T., Eisenberg D.S.;
RT   "Common fibrillar spines of amyloid-beta and human islet amyloid
RT   polypeptide revealed by microelectron diffraction and structure-based
RT   inhibitors.";
RL   J. Biol. Chem. 293:2888-2902(2018).
RN   [127]
RP   REVIEW ON VARIANTS.
RX   PubMed=1363811; DOI=10.1038/ng0792-233;
RA   Hardy J.;
RT   "Framing beta-amyloid.";
RL   Nat. Genet. 1:233-234(1992).
RN   [128]
RP   VARIANT CAA-APP GLN-693.
RX   PubMed=2111584; DOI=10.1126/science.2111584;
RA   Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D.,
RA   Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W.,
RA   Frangione B.;
RT   "Mutation of the Alzheimer's disease amyloid gene in hereditary
RT   cerebral hemorrhage, Dutch type.";
RL   Science 248:1124-1126(1990).
RN   [129]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1671712; DOI=10.1038/349704a0;
RA   Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F.,
RA   Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R.,
RA   Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M.,
RA   Roses A.D., Williamson R., Rossor M., Owen M., Hardy J.;
RT   "Segregation of a missense mutation in the amyloid precursor protein
RT   gene with familial Alzheimer's disease.";
RL   Nature 349:704-706(1991).
RN   [130]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1908231; DOI=10.1016/0006-291X(91)91011-Z;
RA   Yoshioka K., Miki T., Katsuya T., Ogihara T., Sakaki Y.;
RT   "The 717Val-->Ile substitution in amyloid precursor protein is
RT   associated with familial Alzheimer's disease regardless of ethnic
RT   groups.";
RL   Biochem. Biophys. Res. Commun. 178:1141-1146(1991).
RN   [131]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1678058; DOI=10.1016/0140-6736(91)91612-X;
RA   Naruse S., Igarashi S., Kobayashi H., Aoki K., Inuzuka T., Kaneko K.,
RA   Shimizu T., Iihara K., Kojima T., Miyatake T., Tsuji S.;
RT   "Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein
RT   gene in Japanese familial Alzheimer's disease.";
RL   Lancet 337:978-979(1991).
RN   [132]
RP   VARIANT AD1 GLY-717.
RX   PubMed=1944558; DOI=10.1038/353844a0;
RA   Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D.,
RA   Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M.;
RT   "Early-onset Alzheimer's disease caused by mutations at codon 717 of
RT   the beta-amyloid precursor protein gene.";
RL   Nature 353:844-846(1991).
RN   [133]
RP   VARIANT AD1 PHE-717.
RX   PubMed=1925564; DOI=10.1126/science.1925564;
RA   Murrell J.R., Farlow M., Ghetti B., Benson M.D.;
RT   "A mutation in the amyloid precursor protein associated with
RT   hereditary Alzheimer's disease.";
RL   Science 254:97-99(1991).
RN   [134]
RP   VARIANT AD1 GLY-693.
RX   PubMed=1415269;
RA   Kamino K., Orr H.T., Payami H., Wijsman E.M., Alonso M.E., Pulst S.M.,
RA   Anderson L., O'Dahl S., Nemens E., White J.A., Sadovnick A.D.,
RA   Ball M.J., Kaye J., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Korenberg J.R., Sharma V., Kukull W., Larson E., Heston L.L.,
RA   Martin G.M., Bird T.D., Schellenberg G.D.;
RT   "Linkage and mutational analysis of familial Alzheimer disease
RT   kindreds for the APP gene region.";
RL   Am. J. Hum. Genet. 51:998-1014(1992).
RN   [135]
RP   VARIANT AD1 GLY-692.
RX   PubMed=1303239; DOI=10.1038/ng0692-218;
RA   Hendriks L., van Duijn C.M., Cras P., Cruts M., Van Hul W.,
RA   van Harskamp F., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Martin J.J., Hofman A., Van Broeckhoven C.;
RT   "Presenile dementia and cerebral haemorrhage linked to a mutation at
RT   codon 692 of the beta-amyloid precursor protein gene.";
RL   Nat. Genet. 1:218-221(1992).
RN   [136]
RP   VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=1302033; DOI=10.1038/ng0892-345;
RA   Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B.,
RA   Lannfelt L.;
RT   "A pathogenic mutation for probable Alzheimer's disease in the APP
RT   gene at the N-terminus of beta-amyloid.";
RL   Nat. Genet. 1:345-347(1992).
RN   [137]
RP   CHARACTERIZATION OF VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=1465129; DOI=10.1038/360672a0;
RA   Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y.,
RA   Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J.;
RT   "Mutation of the beta-amyloid precursor protein in familial
RT   Alzheimer's disease increases beta-protein production.";
RL   Nature 360:672-674(1992).
RN   [138]
RP   VARIANT VAL-713.
RX   PubMed=1307241; DOI=10.1038/ng0792-306;
RA   Jones C.T., Morris S., Yates C.M., Moffoot A., Sharpe C.,
RA   Brock D.J.H., St Clair D.;
RT   "Mutation in codon 713 of the beta amyloid precursor protein gene
RT   presenting with schizophrenia.";
RL   Nat. Genet. 1:306-309(1992).
RN   [139]
RP   VARIANT AD1 THR-713.
RX   PubMed=1303275; DOI=10.1038/ng1292-255;
RA   Carter D.A., Desmarais E., Bellis M., Campion D., Clerget-Darpoux F.,
RA   Brice A., Agid Y., Jaillard-Serradt A., Mallet J.;
RT   "More missense in amyloid gene.";
RL   Nat. Genet. 2:255-256(1992).
RN   [140]
RP   VARIANTS AD1 ILE-717 AND PHE-717.
RX   PubMed=8267572; DOI=10.1006/bbrc.1993.2491;
RA   Liepnieks J.J., Ghetti B., Farlow M., Roses A.D., Benson M.D.;
RT   "Characterization of amyloid fibril beta-peptide in familial
RT   Alzheimer's disease with APP717 mutations.";
RL   Biochem. Biophys. Res. Commun. 197:386-392(1993).
RN   [141]
RP   VARIANT ASP-665.
RX   PubMed=8154870; DOI=10.1002/ana.410350410;
RA   Peacock M.L., Murman D.L., Sima A.A.F., Warren J.T. Jr., Roses A.D.,
RA   Fink J.K.;
RT   "Novel amyloid precursor protein gene mutation (codon 665Asp) in a
RT   patient with late-onset Alzheimer's disease.";
RL   Ann. Neurol. 35:432-438(1994).
RN   [142]
RP   VARIANT AD1 PHE-717.
RX   PubMed=8290042; DOI=10.1212/WNL.44.1.105;
RA   Farlow M., Murrell J., Ghetti B., Unverzagt F., Zeldenrust S.,
RA   Benson M.D.;
RT   "Clinical characteristics in a kindred with early-onset Alzheimer's
RT   disease and their linkage to a G-->T change at position 2149 of the
RT   amyloid precursor protein gene.";
RL   Neurology 44:105-111(1994).
RN   [143]
RP   VARIANT AD1 ILE-717.
RX   PubMed=8577393; DOI=10.1016/0304-3940(95)12046-7;
RA   Brooks W.S., Martins R.N., De Voecht J., Nicholson G.A.,
RA   Schofield P.R., Kwok J.B.J., Fisher C., Yeung L.U.,
RA   Van Broeckhoven C.;
RT   "A mutation in codon 717 of the amyloid precursor protein gene in an
RT   Australian family with Alzheimer's disease.";
RL   Neurosci. Lett. 199:183-186(1995).
RN   [144]
RP   CHARACTERIZATION OF VARIANTS AD1 GLY-717; ILE-717 AND PHE-717.
RX   PubMed=8886002; DOI=10.1006/bbrc.1996.1577;
RA   Maruyama K., Tomita T., Shinozaki K., Kume H., Asada H., Saido T.C.,
RA   Ishiura S., Iwatsubo T., Obata K.;
RT   "Familial Alzheimer's disease-linked mutations at Val717 of amyloid
RT   precursor protein are specific for the increased secretion of A beta
RT   42(43).";
RL   Biochem. Biophys. Res. Commun. 227:730-735(1996).
RN   [145]
RP   VARIANT AD1 VAL-716.
RX   PubMed=9328472; DOI=10.1093/hmg/6.12.2087;
RA   Eckman C.B., Mehta N.D., Crook R., Perez-Tur J., Prihar G.,
RA   Pfeiffer E., Graff-Radford N., Hinder P., Yager D., Zenk B.,
RA   Refolo L.M., Prada C.M., Younkin S.G., Hutton M., Hardy J.;
RT   "A new pathogenic mutation in the APP gene (I716V) increases the
RT   relative proportion of A beta 42(43).";
RL   Hum. Mol. Genet. 6:2087-2089(1997).
RN   [146]
RP   VARIANT AD1 GLY-692, AND CHARACTERIZATION OF PHENOTYPE.
RX   PubMed=9754958; DOI=10.1007/s004010050892;
RA   Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C.M.,
RA   Stefanko S.Z., Hofman A., Kros J.M., Van Broeckhoven C., Martin J.J.;
RT   "Presenile Alzheimer dementia characterized by amyloid angiopathy and
RT   large amyloid core type senile plaques in the APP 692Ala-->Gly
RT   mutation.";
RL   Acta Neuropathol. 96:253-260(1998).
RN   [147]
RP   VARIANT AD1 MET-715, AND CHARACTERIZATION OF VARIANT AD1 MET-715.
RX   PubMed=10097173; DOI=10.1073/pnas.96.7.4119;
RA   Ancolio K., Dumanchin C., Barelli H., Warter J.-M., Brice A.,
RA   Campion D., Frebourg T., Checler F.;
RT   "Unusual phenotypic alteration of beta amyloid precursor protein
RT   (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation
RT   responsible for probable early-onset Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4119-4124(1999).
RN   [148]
RP   VARIANT AD1 ILE-717.
RX   PubMed=10631141; DOI=10.1086/302702;
RA   Finckh U., Mueller-Thomsen T., Mann U., Eggers C., Marksteiner J.,
RA   Meins W., Binetti G., Alberici A., Hock C., Nitsch R.M., Gal A.;
RT   "High prevalence of pathogenic mutations in patients with early-onset
RT   dementia detected by sequence analyses of four different genes.";
RL   Am. J. Hum. Genet. 66:110-117(2000).
RN   [149]
RP   VARIANT AD1 PRO-723.
RX   PubMed=10665499;
RX   DOI=10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.0.CO;2-8;
RA   Kwok J.B.J., Li Q.X., Hallupp M., Whyte S., Ames D., Beyreuther K.,
RA   Masters C.L., Schofield P.R.;
RT   "Novel Leu723Pro amyloid precursor protein mutation increases amyloid
RT   beta42(43) peptide levels and induces apoptosis.";
RL   Ann. Neurol. 47:249-253(2000).
RN   [150]
RP   VARIANT AD1 LEU-717.
RX   PubMed=10867787; DOI=10.1001/archneur.57.6.885;
RA   Murrell J.R., Hake A.M., Quaid K.A., Farlow M.R., Ghetti B.;
RT   "Early-onset Alzheimer disease caused by a new mutation (V717L) in the
RT   amyloid precursor protein gene.";
RL   Arch. Neurol. 57:885-887(2000).
RN   [151]
RP   VARIANT AD1 ILE-714, AND CHARACTERIZATION OF VARIANTS AD1 ILE-714 AND
RP   ILE-717.
RX   PubMed=11063718; DOI=10.1093/hmg/9.18.2589;
RA   Kumar-Singh S., De Jonghe C., Cruts M., Kleinert R., Wang R.,
RA   Mercken M., De Strooper B., Vanderstichele H., Loefgren A.,
RA   Vanderhoeven I., Backhovens H., Vanmechelen E., Kroisel P.M.,
RA   Van Broeckhoven C.;
RT   "Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase
RT   site mutation points to an essential role for N-truncated A beta(42)
RT   in Alzheimer's disease.";
RL   Hum. Mol. Genet. 9:2589-2598(2000).
RN   [152]
RP   CHARACTERIZATION OF VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=10677483; DOI=10.1073/pnas.97.4.1456;
RA   Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J.;
RT   "Human aspartic protease memapsin 2 cleaves the beta-secretase site of
RT   beta-amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:1456-1460(2000).
RN   [153]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=11409420; DOI=10.1002/ana.1009;
RA   Grabowski T.J., Cho H.S., Vonsattel J.P.G., Rebeck G.W.,
RA   Greenberg S.M.;
RT   "Novel amyloid precursor protein mutation in an Iowa family with
RT   dementia and severe cerebral amyloid angiopathy.";
RL   Ann. Neurol. 49:697-705(2001).
RN   [154]
RP   CHARACTERIZATION OF VARIANT AD1 GLY-692.
RX   PubMed=11311152;
RA   Walsh D.M., Hartley D.M., Condron M.M., Selkoe D.J., Teplow D.B.;
RT   "In vitro studies of amyloid beta-protein fibril assembly and toxicity
RT   provide clues to the aetiology of Flemish variant (Ala692-->Gly)
RT   Alzheimer's disease.";
RL   Biochem. J. 355:869-877(2001).
RN   [155]
RP   VARIANT AD1 GLY-693.
RX   PubMed=11528419; DOI=10.1038/nn0901-887;
RA   Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M.,
RA   Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B.,
RA   Younkin S.G., Naeslund J., Lannfelt L.;
RT   "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by
RT   enhanced Abeta protofibril formation.";
RL   Nat. Neurosci. 4:887-893(2001).
RN   [156]
RP   VARIANT AD1 ALA-714.
RX   PubMed=12034808; DOI=10.1212/WNL.58.10.1574;
RA   Pasalar P., Najmabadi H., Noorian A.R., Moghimi B., Jannati A.,
RA   Soltanzadeh A., Krefft T., Crook R., Hardy J.;
RT   "An Iranian family with Alzheimer's disease caused by a novel APP
RT   mutation (Thr714Ala).";
RL   Neurology 58:1574-1575(2002).
RN   [157]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=12654973; DOI=10.1212/01.WNL.0000050140.10044.A8;
RA   Greenberg S.M., Shin Y., Grabowski T.J., Cooper G.E., Rebeck G.W.,
RA   Iglesias S., Chapon F., Tournier-Lasserve E., Baron J.-C.;
RT   "Hemorrhagic stroke associated with the Iowa amyloid precursor protein
RT   mutation.";
RL   Neurology 60:1020-1022(2003).
RN   [158]
RP   VARIANT AD1 THR-713.
RX   PubMed=15365148; DOI=10.1212/01.WNL.0000137048.80666.86;
RA   Rossi G., Giaccone G., Maletta R., Morbin M., Capobianco R.,
RA   Mangieri M., Giovagnoli A.R., Bizzi A., Tomaino C., Perri M.,
RA   Di Natale M., Tagliavini F., Bugiani O., Bruni A.C.;
RT   "A family with Alzheimer disease and strokes associated with A713T
RT   mutation of the APP gene.";
RL   Neurology 63:910-912(2004).
RN   [159]
RP   VARIANT CAA-APP VAL-705.
RX   PubMed=16178030; DOI=10.1002/ana.20571;
RA   Obici L., Demarchi A., de Rosa G., Bellotti V., Marciano S.,
RA   Donadei S., Arbustini E., Palladini G., Diegoli M., Genovese E.,
RA   Ferrari G., Coverlizza S., Merlini G.;
RT   "A novel AbetaPP mutation exclusively associated with cerebral amyloid
RT   angiopathy.";
RL   Ann. Neurol. 58:639-644(2005).
RN   [160]
RP   VARIANT AD1 ILE-714.
RX   PubMed=15668448; DOI=10.1212/01.WNL.0000149761.70566.3E;
RA   Edwards-Lee T., Ringman J.M., Chung J., Werner J., Morgan A.,
RA   St George-Hyslop P.H., Thompson P., Dutton R., Mlikotic A.,
RA   Rogaeva E., Hardy J.;
RT   "An African American family with early-onset Alzheimer disease and an
RT   APP (T714I) mutation.";
RL   Neurology 64:377-379(2005).
RN   [161]
RP   VARIANT CAA-APP LYS-693.
RX   PubMed=20697050; DOI=10.1001/archneurol.2010.178;
RA   Bugiani O., Giaccone G., Rossi G., Mangieri M., Capobianco R.,
RA   Morbin M., Mazzoleni G., Cupidi C., Marcon G., Giovagnoli A.,
RA   Bizzi A., Di Fede G., Puoti G., Carella F., Salmaggi A., Romorini A.,
RA   Patruno G.M., Magoni M., Padovani A., Tagliavini F.;
RT   "Hereditary cerebral hemorrhage with amyloidosis associated with the
RT   E693K mutation of APP.";
RL   Arch. Neurol. 67:987-995(2010).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to
CC       neurite growth, neuronal adhesion and axonogenesis. Interaction
CC       between APP molecules on neighboring cells promotes synaptogenesis
CC       (PubMed:25122912). Involved in cell mobility and transcription
CC       regulation through protein-protein interactions. Can promote
CC       transcription activation through binding to APBB1-KAT5 and
CC       inhibits Notch signaling through interaction with Numb. Couples to
CC       apoptosis-inducing pathways such as those mediated by G(O) and
CC       JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as
CC       a kinesin I membrane receptor, mediating the axonal transport of
CC       beta-secretase and presenilin 1. Involved in copper
CC       homeostasis/oxidative stress through copper ion reduction. In
CC       vitro, copper-metallated APP induces neuronal death directly or is
CC       potentiated through Cu(2+)-mediated low-density lipoprotein
CC       oxidation. Can regulate neurite outgrowth through binding to
CC       components of the extracellular matrix such as heparin and
CC       collagen I and IV. The splice isoforms that contain the BPTI
CC       domain possess protease inhibitor activity. Induces a AGER-
CC       dependent pathway that involves activation of p38 MAPK, resulting
CC       in internalization of amyloid-beta peptide and leading to
CC       mitochondrial dysfunction in cultured cortical neurons. Provides
CC       Cu(2+) ions for GPC1 which are required for release of nitric
CC       oxide (NO) and subsequent degradation of the heparan sulfate
CC       chains on GPC1. {ECO:0000250, ECO:0000269|PubMed:25122912}.
CC   -!- FUNCTION: Amyloid-beta peptides are lipophilic metal chelators
CC       with metal-reducing activity. Bind transient metals such as
CC       copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to
CC       Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more
CC       effective reductant than amyloid-beta protein 40. Amyloid-beta
CC       peptides bind to lipoproteins and apolipoproteins E and J in the
CC       CSF and to HDL particles in plasma, inhibiting metal-catalyzed
CC       oxidation of lipoproteins. APP42-beta may activate mononuclear
CC       phagocytes in the brain and elicit inflammatory responses.
CC       Promotes both tau aggregation and TPK II-mediated phosphorylation.
CC       Interaction with overexpressed HADH2 leads to oxidative stress and
CC       neurotoxicity. Also binds GPC1 in lipid rafts.
CC   -!- FUNCTION: Appicans elicit adhesion of neural cells to the
CC       extracellular matrix and may regulate neurite outgrowth in the
CC       brain. {ECO:0000250}.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal
CC       apoptosis.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and
CC       axons (via caspase-6).
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA
CC       family, MAPK8IP1, SHC1 and, NUMB and DAB1 (By similarity). Binding
CC       to DAB1 inhibits its serine phosphorylation (By similarity).
CC       Interacts (via NPXY motif) with DAB2 (via PID domain); the
CC       interaction is impaired by tyrosine phosphorylation of the NPXY
CC       motif. Also interacts with GPCR-like protein BPP, APPBP1, IB1,
CC       KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1. In vitro,
CC       it binds MAPT via the MT-binding domains (By similarity).
CC       Associates with microtubules in the presence of ATP and in a
CC       kinesin-dependent manner (By similarity). Interacts, through a C-
CC       terminal domain, with GNAO1. Amyloid-beta protein 42 binds CHRNA7
CC       in hippocampal neurons. Amyloid-beta associates with HADH2.
CC       Soluble APP binds, via its N-terminal head, to FBLN1. Interacts
CC       with CPEB1 and AGER (By similarity). Interacts with ANKS1B and
CC       TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts
CC       with IDE. Can form homodimers; dimerization is enhanced in the
CC       presence of Cu(2+) ions (PubMed:25122912). Can form homodimers;
CC       this is promoted by heparin binding. Amyloid-beta protein 40
CC       interacts with S100A9. CTF-alpha product of APP interacts with
CC       GSAP. Interacts with SORL1. Interacts with PLD3. Interacts with
CC       VDAC1 (PubMed:25168729). Interacts with NSG1; could regulate APP
CC       processing (By similarity). Amyloid-beta protein 42 interacts with
CC       FPR2 (PubMed:11689470). Interacts with SYT7 (By similarity).
CC       {ECO:0000250|UniProtKB:P12023, ECO:0000269|PubMed:10681545,
CC       ECO:0000269|PubMed:10816430, ECO:0000269|PubMed:11238726,
CC       ECO:0000269|PubMed:11278849, ECO:0000269|PubMed:11438549,
CC       ECO:0000269|PubMed:11517218, ECO:0000269|PubMed:11544248,
CC       ECO:0000269|PubMed:11689470, ECO:0000269|PubMed:11724784,
CC       ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:11943163,
CC       ECO:0000269|PubMed:15347684, ECO:0000269|PubMed:16174740,
CC       ECO:0000269|PubMed:17051221, ECO:0000269|PubMed:17895381,
CC       ECO:0000269|PubMed:18468999, ECO:0000269|PubMed:19225519,
CC       ECO:0000269|PubMed:19366692, ECO:0000269|PubMed:19901339,
CC       ECO:0000269|PubMed:20212142, ECO:0000269|PubMed:20811458,
CC       ECO:0000269|PubMed:22457725, ECO:0000269|PubMed:24336208,
CC       ECO:0000269|PubMed:25122912, ECO:0000269|PubMed:25168729,
CC       ECO:0000269|PubMed:8446172, ECO:0000269|PubMed:8626687,
CC       ECO:0000269|PubMed:8855266, ECO:0000269|PubMed:8887653,
CC       ECO:0000269|PubMed:9300481, ECO:0000269|PubMed:9338779,
CC       ECO:0000269|PubMed:9843960, ECO:0000269|PubMed:9890987}.
CC   -!- INTERACTION:
CC       Self; NbExp=106; IntAct=EBI-77613, EBI-77613;
CC       Q306T3:- (xeno); NbExp=3; IntAct=EBI-77613, EBI-8294101;
CC       P31696:AGRN (xeno); NbExp=3; IntAct=EBI-2431589, EBI-457650;
CC       Q02410:APBA1; NbExp=3; IntAct=EBI-77613, EBI-368690;
CC       O00213:APBB1; NbExp=5; IntAct=EBI-77613, EBI-81694;
CC       Q92870:APBB2; NbExp=2; IntAct=EBI-77613, EBI-79277;
CC       P51693:APLP1; NbExp=2; IntAct=EBI-302641, EBI-74648;
CC       Q06481:APLP2; NbExp=2; IntAct=EBI-302641, EBI-79306;
CC       P02647:APOA1; NbExp=5; IntAct=EBI-77613, EBI-701692;
CC       P02649:APOE; NbExp=3; IntAct=EBI-2431589, EBI-1222467;
CC       Q13867:BLMH; NbExp=2; IntAct=EBI-302641, EBI-718504;
CC       P15253:CALR (xeno); NbExp=3; IntAct=EBI-77613, EBI-9005200;
CC       P27797:CALR; NbExp=2; IntAct=EBI-77613, EBI-1049597;
CC       Q8K3H7:CALR (xeno); NbExp=2; IntAct=EBI-3894543, EBI-9005068;
CC       P36544:CHRNA7; NbExp=3; IntAct=EBI-821758, EBI-79333;
CC       P10909:CLU; NbExp=3; IntAct=EBI-2431589, EBI-1104674;
CC       P39060:COL18A1; NbExp=2; IntAct=EBI-821758, EBI-2566375;
CC       P07339:CTSD; NbExp=2; IntAct=EBI-77613, EBI-2115097;
CC       O75955:FLOT1; NbExp=5; IntAct=EBI-77613, EBI-603643;
CC       Q9NZU0:FLRT3; NbExp=3; IntAct=EBI-302641, EBI-1057092;
CC       P01100:FOS; NbExp=3; IntAct=EBI-77613, EBI-852851;
CC       P46089:GPR3; NbExp=2; IntAct=EBI-302641, EBI-3909653;
CC       A4D1B5:GSAP; NbExp=3; IntAct=EBI-77613, EBI-15875313;
CC       Q9NSC5:HOMER3; NbExp=3; IntAct=EBI-302661, EBI-748420;
CC       Q99714:HSD17B10; NbExp=4; IntAct=EBI-77613, EBI-79964;
CC       P14735-1:IDE; NbExp=3; IntAct=EBI-2431589, EBI-15607031;
CC       O43736:ITM2A; NbExp=3; IntAct=EBI-302641, EBI-2431769;
CC       P05412:JUN; NbExp=2; IntAct=EBI-77613, EBI-852823;
CC       Q68DU8:KCTD16; NbExp=3; IntAct=EBI-302641, EBI-20768174;
CC       Q8N423:LILRB2; NbExp=7; IntAct=EBI-821758, EBI-2816428;
CC       P97484:Lilrb3 (xeno); NbExp=8; IntAct=EBI-821758, EBI-15728641;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-77613, EBI-476263;
CC       P10636:MAPT; NbExp=5; IntAct=EBI-77613, EBI-366182;
CC       Q93074:MED12; NbExp=2; IntAct=EBI-77613, EBI-394357;
CC       P03897:MT-ND3; NbExp=2; IntAct=EBI-821758, EBI-1246249;
CC       P07196:NEFL; NbExp=2; IntAct=EBI-77613, EBI-475646;
CC       P21359:NF1; NbExp=3; IntAct=EBI-77613, EBI-1172917;
CC       P08138:NGFR; NbExp=2; IntAct=EBI-77613, EBI-1387782;
CC       P07174:Ngfr (xeno); NbExp=2; IntAct=EBI-2431589, EBI-1038810;
CC       P61457:PCBD1; NbExp=2; IntAct=EBI-77613, EBI-740475;
CC       Q15113:PCOLCE; NbExp=4; IntAct=EBI-821758, EBI-8869614;
CC       P30101:PDIA3; NbExp=3; IntAct=EBI-77613, EBI-979862;
CC       Q13526:PIN1; NbExp=2; IntAct=EBI-302641, EBI-714158;
CC       Q5JRX3-1:PITRM1; NbExp=3; IntAct=EBI-2431589, EBI-16109799;
CC       P60201:PLP1; NbExp=5; IntAct=EBI-302641, EBI-8653150;
CC       P04156:PRNP; NbExp=3; IntAct=EBI-77613, EBI-977302;
CC       P49768:PSEN1; NbExp=6; IntAct=EBI-77613, EBI-297277;
CC       P11686-1:SFTPC; NbExp=4; IntAct=EBI-821758, EBI-16143688;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-77613, EBI-78835;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-77613, EBI-79084;
CC       Q9NP59:SLC40A1; NbExp=5; IntAct=EBI-77613, EBI-725153;
CC       Q8BGY9:Slc5a7 (xeno); NbExp=2; IntAct=EBI-77613, EBI-2010752;
CC       Q92673:SORL1; NbExp=3; IntAct=EBI-2431589, EBI-1171329;
CC       Q9HCB6:SPON1; NbExp=3; IntAct=EBI-302641, EBI-2431846;
CC       O95793:STAU1; NbExp=2; IntAct=EBI-302641, EBI-358174;
CC       P01137:TGFB1; NbExp=3; IntAct=EBI-77613, EBI-779636;
CC       P61812:TGFB2; NbExp=7; IntAct=EBI-77613, EBI-779581;
CC       P21980:TGM2; NbExp=2; IntAct=EBI-821758, EBI-727668;
CC       Q13625:TP53BP2; NbExp=3; IntAct=EBI-77613, EBI-77642;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10383380,
CC       ECO:0000269|PubMed:20580937, ECO:0000305|PubMed:25122912}; Single-
CC       pass type I membrane protein {ECO:0000305|PubMed:10383380,
CC       ECO:0000305|PubMed:25122912}. Membrane
CC       {ECO:0000269|PubMed:2900137, ECO:0000305|PubMed:22584060}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:2900137,
CC       ECO:0000305|PubMed:22584060}. Perikaryon
CC       {ECO:0000269|PubMed:10341243}. Cell projection, growth cone
CC       {ECO:0000269|PubMed:10341243}. Membrane, clathrin-coated pit
CC       {ECO:0000269|PubMed:20580937}. Early endosome
CC       {ECO:0000269|PubMed:20580937}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:20580937, ECO:0000269|PubMed:25122912}.
CC       Note=Cell surface protein that rapidly becomes internalized via
CC       clathrin-coated pits. Only a minor proportion is present at the
CC       cell membrane; most of the protein is present in intracellular
CC       vesicles (PubMed:20580937). During maturation, the immature APP
CC       (N-glycosylated in the endoplasmic reticulum) moves to the Golgi
CC       complex where complete maturation occurs (O-glycosylated and
CC       sulfated). After alpha-secretase cleavage, soluble APP is released
CC       into the extracellular space and the C-terminal is internalized to
CC       endosomes and lysosomes. Some APP accumulates in secretory
CC       transport vesicles leaving the late Golgi compartment and returns
CC       to the cell surface. APP sorts to the basolateral surface in
CC       epithelial cells. During neuronal differentiation, the Thr-743
CC       phosphorylated form is located mainly in growth cones, moderately
CC       in neurites and sparingly in the cell body (PubMed:10341243).
CC       Casein kinase phosphorylation can occur either at the cell surface
CC       or within a post-Golgi compartment. Associates with GPC1 in
CC       perinuclear compartments. Colocalizes with SORL1 in a vesicular
CC       pattern in cytoplasm and perinuclear regions.
CC       {ECO:0000269|PubMed:10341243, ECO:0000269|PubMed:20580937}.
CC   -!- SUBCELLULAR LOCATION: Soluble APP-beta: Secreted
CC       {ECO:0000269|PubMed:10656250}.
CC   -!- SUBCELLULAR LOCATION: Amyloid-beta protein 42: Cell surface.
CC       Note=Associates with FPR2 at the cell surface and the complex is
CC       then rapidly internalized. {ECO:0000269|PubMed:11689470}.
CC   -!- SUBCELLULAR LOCATION: Gamma-secretase C-terminal fragment 59:
CC       Nucleus {ECO:0000269|PubMed:11544248}. Cytoplasm
CC       {ECO:0000269|PubMed:11544248}. Note=located to both the cytoplasm
CC       and nuclei of neurons. It can be translocated to the nucleus
CC       through association with APBB1 (Fe65).
CC       {ECO:0000269|PubMed:11544248}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist. Experimental
CC         confirmation may be lacking for some isoforms.;
CC       Name=APP770; Synonyms=PreA4 770;
CC         IsoId=P05067-1; Sequence=Displayed;
CC         Note=A major isoform.;
CC       Name=APP305;
CC         IsoId=P05067-2; Sequence=VSP_000005, VSP_000006;
CC       Name=L-APP677;
CC         IsoId=P05067-3; Sequence=VSP_000002, VSP_000004, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP695; Synonyms=PreA4 695;
CC         IsoId=P05067-4; Sequence=VSP_000002, VSP_000004;
CC         Note=A major isoform.;
CC       Name=L-APP696;
CC         IsoId=P05067-5; Sequence=VSP_000002, VSP_000003, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP714;
CC         IsoId=P05067-6; Sequence=VSP_000002, VSP_000003;
CC       Name=L-APP733;
CC         IsoId=P05067-7; Sequence=VSP_000007, VSP_000008, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP751; Synonyms=PreA4 751;
CC         IsoId=P05067-8; Sequence=VSP_000007, VSP_000008;
CC         Note=A major isoform.;
CC       Name=L-APP752;
CC         IsoId=P05067-9; Sequence=VSP_000009;
CC       Name=APP639;
CC         IsoId=P05067-10; Sequence=VSP_009116, VSP_009117, VSP_009118;
CC       Name=11;
CC         IsoId=P05067-11; Sequence=VSP_045446, VSP_045447;
CC   -!- TISSUE SPECIFICITY: Expressed in all fetal tissues examined with
CC       highest levels in brain, kidney, heart and spleen. Weak expression
CC       in liver. In adult brain, highest expression found in the frontal
CC       lobe of the cortex and in the anterior perisylvian cortex-
CC       opercular gyri. Moderate expression in the cerebellar cortex, the
CC       posterior perisylvian cortex-opercular gyri and the temporal
CC       associated cortex. Weak expression found in the striate, extra-
CC       striate and motor cortices. Expressed in cerebrospinal fluid, and
CC       plasma. Isoform APP695 is the predominant form in neuronal tissue,
CC       isoform APP751 and isoform APP770 are widely expressed in non-
CC       neuronal cells. Isoform APP751 is the most abundant form in T-
CC       lymphocytes. Appican is expressed in astrocytes.
CC       {ECO:0000269|PubMed:12859342, ECO:0000269|PubMed:1406936}.
CC   -!- INDUCTION: Increased levels during neuronal differentiation.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
CC       sorting of membrane proteins to the basolateral surface of
CC       epithelial cells. {ECO:0000269|PubMed:9843960}.
CC   -!- DOMAIN: The GFLD subdomain binds Cu(2+) ions; this promotes
CC       homodimerization. {ECO:0000269|PubMed:25122912}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. However, additional amino acids either N- or C-
CC       terminal to the NPXY motif are often required for complete
CC       interaction. The PID domain-containing proteins which bind APP
CC       require the YENPTY motif for full interaction. These interactions
CC       are independent of phosphorylation on the terminal tyrosine
CC       residue. The YENPXY site is also involved in clathrin-mediated
CC       endocytosis. {ECO:0000269|PubMed:10383380}.
CC   -!- DOMAIN: The C-terminal region can bind zinc ions; this favors
CC       dimerization and formation of higher oligomers.
CC       {ECO:0000269|PubMed:26898943, ECO:0000269|PubMed:28570778}.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-
CC       secretase leads to generation and extracellular release of soluble
CC       APP peptides, S-APP-alpha and S-APP-beta, and the retention of
CC       corresponding membrane-anchored C-terminal fragments, C80, C83 and
CC       C99. Subsequent processing of C80 and C83 by gamma-secretase
CC       yields P3 peptides. This is the major secretory pathway and is
CC       non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated
CC       gamma-secretase processing of C99 releases the amyloid-beta
CC       proteins, amyloid-beta protein 40 and amyloid-beta protein 42,
CC       major components of amyloid plaques, and the cytotoxic C-terminal
CC       fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Many
CC       other minor amyloid-beta peptides, amyloid-beta 1-X peptides, are
CC       found in cerebral spinal fluid (CSF) including the amyloid-beta X-
CC       15 peptides, produced from the cleavage by alpha-secretase and all
CC       terminating at Gln-686. {ECO:0000269|PubMed:10656250}.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal
CC       apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9
CC       results in the production of the neurotoxic C31 peptide and the
CC       increased production of amyloid-beta peptides.
CC   -!- PTM: N-glycosylated (PubMed:2900137). N- and O-glycosylated. O-
CC       glycosylation on Ser and Thr residues with core 1 or possibly core
CC       8 glycans. Partial tyrosine glycosylation (Tyr-681) is found on
CC       some minor, short amyloid-beta peptides (amyloid-beta 1-15, 1-16,
CC       1-17, 1-18, 1-19 and 1-20) but not found on amyloid-beta protein
CC       38, amyloid-beta protein 40 nor on amyloid-beta protein 42.
CC       Modification on a tyrosine is unusual and is more prevelant in AD
CC       patients. Glycans had Neu5AcHex(Neu5Ac)HexNAc-O-Tyr,
CC       Neu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr and O-
CC       AcNeu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr structures, where O-Ac is O-
CC       acetylation of Neu5Ac. Neu5AcNeu5Ac is most likely Neu5Ac
CC       2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage
CC       sites may influence the proteolytic processing. Appicans are L-APP
CC       isoforms with O-linked chondroitin sulfate.
CC       {ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:21712440,
CC       ECO:0000269|PubMed:22576872, ECO:0000269|PubMed:2900137}.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific. Phosphorylation can affect APP
CC       processing, neuronal differentiation and interaction with other
CC       proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5
CC       kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-
CC       cycle dependent manner with maximal levels at the G2/M phase and,
CC       in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a
CC       conformational change which reduces binding of Fe65 family
CC       members. Phosphorylation on Tyr-757 is required for SHC binding.
CC       Phosphorylated in the extracellular domain by casein kinases on
CC       both soluble and membrane-bound APP. This phosphorylation is
CC       inhibited by heparin. {ECO:0000269|PubMed:10341243,
CC       ECO:0000269|PubMed:11146006, ECO:0000269|PubMed:11517218,
CC       ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:8131745,
CC       ECO:0000269|PubMed:8999878}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation
CC       of a disulfide bond. In vitro, the APP-Cu(+) complex in the
CC       presence of hydrogen peroxide results in an increased production
CC       of amyloid-beta-containing peptides.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface
CC       APP by beta-secretase to release sAPP-beta which is further
CC       cleaved to release an N-terminal fragment of APP (N-APP).
CC   -!- PTM: Amyloid-beta peptides are degraded by IDE.
CC   -!- MASS SPECTROMETRY: Mass=6461.6; Method=MALDI; Range=712-767;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=6451.6; Method=MALDI; Range=714-770;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=6436.8; Method=MALDI; Range=715-769;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=5752.5; Method=MALDI; Range=719-767;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- DISEASE: Alzheimer disease 1 (AD1) [MIM:104300]: A familial early-
CC       onset form of Alzheimer disease. It can be associated with
CC       cerebral amyloid angiopathy. Alzheimer disease is a
CC       neurodegenerative disorder characterized by progressive dementia,
CC       loss of cognitive abilities, and deposition of fibrillar amyloid
CC       proteins as intraneuronal neurofibrillary tangles, extracellular
CC       amyloid plaques and vascular amyloid deposits. The major
CC       constituents of these plaques are neurotoxic amyloid-beta protein
CC       40 and amyloid-beta protein 42, that are produced by the
CC       proteolysis of the transmembrane APP protein. The cytotoxic C-
CC       terminal fragments (CTFs) and the caspase-cleaved products, such
CC       as C31, are also implicated in neuronal death.
CC       {ECO:0000269|PubMed:10097173, ECO:0000269|PubMed:10631141,
CC       ECO:0000269|PubMed:10656250, ECO:0000269|PubMed:10665499,
CC       ECO:0000269|PubMed:10677483, ECO:0000269|PubMed:10867787,
CC       ECO:0000269|PubMed:11063718, ECO:0000269|PubMed:11311152,
CC       ECO:0000269|PubMed:11528419, ECO:0000269|PubMed:12034808,
CC       ECO:0000269|PubMed:1302033, ECO:0000269|PubMed:1303239,
CC       ECO:0000269|PubMed:1303275, ECO:0000269|PubMed:1415269,
CC       ECO:0000269|PubMed:1465129, ECO:0000269|PubMed:15201367,
CC       ECO:0000269|PubMed:15365148, ECO:0000269|PubMed:15668448,
CC       ECO:0000269|PubMed:1671712, ECO:0000269|PubMed:1678058,
CC       ECO:0000269|PubMed:1908231, ECO:0000269|PubMed:1925564,
CC       ECO:0000269|PubMed:1944558, ECO:0000269|PubMed:8267572,
CC       ECO:0000269|PubMed:8290042, ECO:0000269|PubMed:8476439,
CC       ECO:0000269|PubMed:8577393, ECO:0000269|PubMed:8886002,
CC       ECO:0000269|PubMed:9328472, ECO:0000269|PubMed:9754958}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cerebral amyloid angiopathy, APP-related (CAA-APP)
CC       [MIM:605714]: A hereditary localized amyloidosis due to amyloid-
CC       beta A4 peptide(s) deposition in the cerebral vessels. The
CC       principal clinical characteristics are recurrent cerebral and
CC       cerebellar hemorrhages, recurrent strokes, cerebral ischemia,
CC       cerebral infarction, and progressive mental deterioration.
CC       Patients develop cerebral hemorrhage because of the severe
CC       cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare
CC       and largely in the form of pre-amyloid lesions or diffuse plaque-
CC       like structures. They are Congo red negative and lack the dense
CC       amyloid cores commonly present in Alzheimer disease. Some affected
CC       individuals manifest progressive aphasic dementia,
CC       leukoencephalopathy, and occipital calcifications.
CC       {ECO:0000269|PubMed:11409420, ECO:0000269|PubMed:12654973,
CC       ECO:0000269|PubMed:16178030, ECO:0000269|PubMed:20697050,
CC       ECO:0000269|PubMed:2111584}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
CC       zinc, can induce histidine-bridging between amyloid-beta molecules
CC       resulting in amyloid-beta-metal aggregates. The affinity for
CC       copper is much higher than for other transient metals and is
CC       increased under acidic conditions. Extracellular zinc-binding
CC       increases binding of heparin to APP and inhibits collagen-binding.
CC       {ECO:0000269|PubMed:26898943, ECO:0000269|PubMed:28570778}.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01217}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58727.1; Type=Miscellaneous discrepancy; Note=Contamination by an Alu repeat.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Alzforum; Note=APP mutations;
CC       URL="https://www.alzforum.org/mutations/search?genes%255B%255D=348";
CC   -!- WEB RESOURCE: Name=AD mutations;
CC       URL="http://www.molgen.ua.ac.be/ADmutations/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/app/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Amyloid beta entry;
CC       URL="https://en.wikipedia.org/wiki/Amyloid_beta";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00264; CAA68374.1; -; mRNA.
DR   EMBL; X13466; CAA31830.1; -; Genomic_DNA.
DR   EMBL; X13467; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13468; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13469; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13470; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13471; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13472; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13473; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13474; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13475; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13476; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13477; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13478; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13479; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13487; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13488; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X06989; CAA30050.1; -; mRNA.
DR   EMBL; M33112; AAB59502.1; -; Genomic_DNA.
DR   EMBL; M34862; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34874; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34876; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34877; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34878; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34879; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34875; AAB59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M34862; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; D87675; BAA22264.1; -; Genomic_DNA.
DR   EMBL; AK312326; BAG35248.1; -; mRNA.
DR   EMBL; AK295621; BAG58500.1; -; mRNA.
DR   EMBL; AY919674; AAW82435.1; -; Genomic_DNA.
DR   EMBL; AP001439; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001440; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001441; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001442; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001443; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09958.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09959.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09960.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09961.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09963.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09965.1; -; Genomic_DNA.
DR   EMBL; BC004369; AAH04369.1; -; mRNA.
DR   EMBL; BC065529; AAH65529.1; -; mRNA.
DR   EMBL; M35675; AAA60163.1; ALT_SEQ; mRNA.
DR   EMBL; M24547; AAC13654.1; -; Genomic_DNA.
DR   EMBL; M24546; AAC13654.1; JOINED; Genomic_DNA.
DR   EMBL; M28373; AAA58727.1; ALT_SEQ; mRNA.
DR   EMBL; X06982; CAA30042.1; -; mRNA.
DR   EMBL; X06981; CAA30041.1; -; mRNA.
DR   EMBL; M18734; AAA51726.1; -; mRNA.
DR   EMBL; M29270; AAA51768.1; -; Genomic_DNA.
DR   EMBL; M29269; AAA51768.1; JOINED; Genomic_DNA.
DR   EMBL; AB066441; BAB71958.2; -; mRNA.
DR   EMBL; M15533; AAA35540.1; -; mRNA.
DR   EMBL; M15532; AAA51564.1; -; mRNA.
DR   EMBL; M37896; AAA51727.1; -; Genomic_DNA.
DR   EMBL; M37895; AAA51727.1; JOINED; Genomic_DNA.
DR   EMBL; S45136; AAB23646.1; -; Genomic_DNA.
DR   EMBL; S60317; AAC60601.2; -; Genomic_DNA.
DR   EMBL; AF282245; AAQ14327.1; -; mRNA.
DR   EMBL; S60721; AAB26263.2; -; mRNA.
DR   EMBL; S61380; AAB26264.2; -; mRNA.
DR   EMBL; S61383; AAB26265.2; -; mRNA.
DR   EMBL; M16765; AAA51722.1; -; mRNA.
DR   CCDS; CCDS13576.1; -. [P05067-1]
DR   CCDS; CCDS13577.1; -. [P05067-4]
DR   CCDS; CCDS33523.1; -. [P05067-8]
DR   CCDS; CCDS46638.1; -. [P05067-10]
DR   CCDS; CCDS56212.1; -. [P05067-11]
DR   CCDS; CCDS56213.1; -. [P05067-9]
DR   PIR; S01442; S01442.
DR   PIR; S02260; QRHUA4.
DR   RefSeq; NP_000475.1; NM_000484.3. [P05067-1]
DR   RefSeq; NP_001129488.1; NM_001136016.3. [P05067-11]
DR   RefSeq; NP_001129601.1; NM_001136129.2. [P05067-10]
DR   RefSeq; NP_001129602.1; NM_001136130.2.
DR   RefSeq; NP_001129603.1; NM_001136131.2.
DR   RefSeq; NP_001191230.1; NM_001204301.1. [P05067-9]
DR   RefSeq; NP_001191231.1; NM_001204302.1. [P05067-7]
DR   RefSeq; NP_001191232.1; NM_001204303.1. [P05067-3]
DR   RefSeq; NP_958816.1; NM_201413.2. [P05067-8]
DR   RefSeq; NP_958817.1; NM_201414.2. [P05067-4]
DR   UniGene; Hs.434980; -.
DR   PDB; 1AAP; X-ray; 1.50 A; A/B=287-344.
DR   PDB; 1AMB; NMR; -; A=672-699.
DR   PDB; 1AMC; NMR; -; A=672-699.
DR   PDB; 1AML; NMR; -; A=672-711.
DR   PDB; 1BA4; NMR; -; A=672-711.
DR   PDB; 1BA6; NMR; -; A=672-711.
DR   PDB; 1BJB; NMR; -; A=672-699.
DR   PDB; 1BJC; NMR; -; A=672-699.
DR   PDB; 1BRC; X-ray; 2.50 A; I=287-342.
DR   PDB; 1CA0; X-ray; 2.10 A; D/I=289-342.
DR   PDB; 1HZ3; NMR; -; A=681-706.
DR   PDB; 1IYT; NMR; -; A=672-713.
DR   PDB; 1MWP; X-ray; 1.80 A; A=28-123.
DR   PDB; 1OWT; NMR; -; A=124-189.
DR   PDB; 1QCM; NMR; -; A=696-706.
DR   PDB; 1QWP; NMR; -; A=696-706.
DR   PDB; 1QXC; NMR; -; A=696-706.
DR   PDB; 1QYT; NMR; -; A=696-706.
DR   PDB; 1TAW; X-ray; 1.80 A; B=287-344.
DR   PDB; 1TKN; NMR; -; A=460-569.
DR   PDB; 1UO7; Model; -; A=672-713.
DR   PDB; 1UO8; Model; -; A=672-713.
DR   PDB; 1UOA; Model; -; A=672-713.
DR   PDB; 1UOI; Model; -; A=672-713.
DR   PDB; 1X11; X-ray; 2.50 A; C/D=754-766.
DR   PDB; 1Z0Q; NMR; -; A=672-713.
DR   PDB; 1ZE7; NMR; -; A=672-687.
DR   PDB; 1ZE9; NMR; -; A=672-687.
DR   PDB; 1ZJD; X-ray; 2.60 A; B=289-344.
DR   PDB; 2BEG; NMR; -; A/B/C/D/E=672-713.
DR   PDB; 2BOM; Model; -; A/B=681-713.
DR   PDB; 2BP4; NMR; -; A=672-687.
DR   PDB; 2FJZ; X-ray; 1.61 A; A=133-189.
DR   PDB; 2FK1; X-ray; 1.60 A; A=133-189.
DR   PDB; 2FK2; X-ray; 1.65 A; A=133-189.
DR   PDB; 2FK3; X-ray; 2.40 A; A/B/C/D/E/F/G/H=133-189.
DR   PDB; 2FKL; X-ray; 2.50 A; A/B=124-189.
DR   PDB; 2FMA; X-ray; 0.85 A; A=133-189.
DR   PDB; 2G47; X-ray; 2.10 A; C/D=672-711.
DR   PDB; 2IPU; X-ray; 1.65 A; P/Q=672-679.
DR   PDB; 2LFM; NMR; -; A=672-711.
DR   PDB; 2LLM; NMR; -; A=686-726.
DR   PDB; 2LMN; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMO; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMP; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LMQ; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LNQ; NMR; -; A/B/C/D/E/F/G/H=672-711.
DR   PDB; 2LOH; NMR; -; A/B=686-726.
DR   PDB; 2LP1; NMR; -; A=671-770.
DR   PDB; 2LZ3; NMR; -; A/B=699-726.
DR   PDB; 2LZ4; NMR; -; A/B=699-726.
DR   PDB; 2M4J; NMR; -; A/B/C/D/E/F/G/H/I=672-711.
DR   PDB; 2M9R; NMR; -; A=672-711.
DR   PDB; 2M9S; NMR; -; A=672-711.
DR   PDB; 2MGT; NMR; -; A/B=672-687.
DR   PDB; 2MJ1; NMR; -; A=688-705.
DR   PDB; 2MPZ; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a=686-711.
DR   PDB; 2MVX; NMR; -; A/B/C/D/E/F/G/H/I/J=672-711.
DR   PDB; 2MXU; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-713.
DR   PDB; 2NAO; NMR; -; A/B/C/D/E/F=672-713.
DR   PDB; 2OTK; NMR; -; C=672-711.
DR   PDB; 2R0W; X-ray; 2.50 A; Q=672-679.
DR   PDB; 2WK3; X-ray; 2.59 A; C/D=672-713.
DR   PDB; 2Y29; X-ray; 2.30 A; A=687-692.
DR   PDB; 2Y2A; X-ray; 1.91 A; A=687-692.
DR   PDB; 2Y3J; X-ray; 1.99 A; A/B/C/D/E/F/G/H=701-706.
DR   PDB; 2Y3K; X-ray; 1.90 A; A/B/C/D/E/F/G/H=706-713.
DR   PDB; 2Y3L; X-ray; 2.10 A; A/B/C/G=706-713.
DR   PDB; 3AYU; X-ray; 2.00 A; B=586-595.
DR   PDB; 3BAE; X-ray; 1.59 A; A=672-699.
DR   PDB; 3BKJ; X-ray; 1.59 A; A=672-687.
DR   PDB; 3DXC; X-ray; 2.10 A; B/D=739-770.
DR   PDB; 3DXD; X-ray; 2.20 A; B/D=739-770.
DR   PDB; 3DXE; X-ray; 2.00 A; B/D=739-770.
DR   PDB; 3GCI; X-ray; 2.04 A; P=707-713.
DR   PDB; 3IFL; X-ray; 1.50 A; P=672-678.
DR   PDB; 3IFN; X-ray; 1.50 A; P=672-711.
DR   PDB; 3IFO; X-ray; 2.15 A; P/Q=672-678.
DR   PDB; 3IFP; X-ray; 2.95 A; P/Q/R/S=672-678.
DR   PDB; 3JQ5; X-ray; 2.03 A; B=672-679.
DR   PDB; 3JQL; X-ray; 1.20 A; B=687-692.
DR   PDB; 3JTI; X-ray; 1.80 A; B=699-706.
DR   PDB; 3KTM; X-ray; 2.70 A; A/B/C/D/E/F/G/H=18-190.
DR   PDB; 3L33; X-ray; 2.48 A; E/F/G/H=290-341.
DR   PDB; 3L81; X-ray; 1.60 A; B=761-767.
DR   PDB; 3MOQ; X-ray; 2.05 A; A/B/C/D=689-712.
DR   PDB; 3MXC; X-ray; 2.00 A; L=754-762.
DR   PDB; 3MXY; X-ray; 2.30 A; L=754-762.
DR   PDB; 3NYJ; X-ray; 3.20 A; A=365-567.
DR   PDB; 3NYL; X-ray; 2.80 A; A=365-570.
DR   PDB; 3OVJ; X-ray; 1.80 A; A/B/C/D=687-692.
DR   PDB; 3OW9; X-ray; 1.80 A; A/B=687-692.
DR   PDB; 3PZZ; X-ray; 1.29 A; A/B=700-705.
DR   PDB; 3Q2X; X-ray; 1.45 A; A=698-703.
DR   PDB; 3SV1; X-ray; 3.30 A; D/E/F=754-767.
DR   PDB; 3U0T; X-ray; 2.50 A; E/F=701-711.
DR   PDB; 3UMH; X-ray; 2.00 A; A=370-575.
DR   PDB; 3UMI; X-ray; 2.40 A; A=370-575.
DR   PDB; 3UMK; X-ray; 2.60 A; A=370-575.
DR   PDB; 4HIX; X-ray; 2.20 A; A=672-699.
DR   PDB; 4JFN; X-ray; 1.75 A; A=23-185.
DR   PDB; 4M1C; X-ray; 3.50 A; G/H=672-711.
DR   PDB; 4MDR; X-ray; 1.85 A; B=758-767.
DR   PDB; 4MVI; X-ray; 1.70 A; B=672-711.
DR   PDB; 4MVK; X-ray; 1.50 A; B=689-694.
DR   PDB; 4MVL; X-ray; 2.30 A; E/F/G/H=672-711.
DR   PDB; 4NGE; X-ray; 2.70 A; B/E=672-711.
DR   PDB; 4OJF; X-ray; 2.00 A; A=672-679.
DR   PDB; 4ONF; X-ray; 2.00 A; P=672-678.
DR   PDB; 4ONG; X-ray; 2.20 A; P=672-711.
DR   PDB; 4PQD; X-ray; 1.33 A; A=22-126.
DR   PDB; 4PWQ; X-ray; 1.40 A; A/B=18-190.
DR   PDB; 4XXD; X-ray; 2.41 A; C/F=683-699.
DR   PDB; 5AEF; EM; 5.00 A; A/B=686-713.
DR   PDB; 5AM8; X-ray; 1.90 A; P/Q/R/S=675-681.
DR   PDB; 5AMB; X-ray; 1.55 A; P/Q=706-713.
DR   PDB; 5BUO; X-ray; 2.31 A; A/B=370-710.
DR   PDB; 5C67; X-ray; 1.83 A; C/E=294-344.
DR   PDB; 5CSZ; X-ray; 1.80 A; D/E=672-682.
DR   PDB; 5HOW; X-ray; 2.29 A; A/B/C/D/E/F=688-705.
DR   PDB; 5HOX; X-ray; 1.90 A; A/B/C/D/E/F=688-707.
DR   PDB; 5HOY; X-ray; 2.29 A; A/B/C/D/E/F=688-707.
DR   PDB; 5KK3; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-713.
DR   PDB; 5LFY; NMR; -; A/B=672-681.
DR   PDB; 5LV0; X-ray; 2.70 A; C/D=706-711.
DR   PDB; 5MY4; X-ray; 2.21 A; C=674-683.
DR   PDB; 5MYO; X-ray; 1.59 A; E=674-683.
DR   PDB; 5MYX; X-ray; 1.49 A; E/F=674-689.
DR   PDB; 5ONP; X-ray; 1.34 A; B=700-704.
DR   PDB; 5ONQ; X-ray; 1.17 A; B=700-704.
DR   PDB; 5OQV; EM; 4.00 A; A/B/C/D/E/F/G/H/I=672-713.
DR   PDB; 5TXD; X-ray; 1.45 A; Z=698-703.
DR   PDB; 5VOS; EM; 1.42 A; A=695-705.
DR   PDB; 5VZY; X-ray; 2.32 A; A=682-696.
DR   PDB; 5W3P; X-ray; 1.92 A; P=672-687.
DR   PDB; 6CO3; X-ray; 2.38 A; Q=672-682.
DR   PDB; 6GFI; X-ray; 2.30 A; C/E=294-346.
DR   PDBsum; 1AAP; -.
DR   PDBsum; 1AMB; -.
DR   PDBsum; 1AMC; -.
DR   PDBsum; 1AML; -.
DR   PDBsum; 1BA4; -.
DR   PDBsum; 1BA6; -.
DR   PDBsum; 1BJB; -.
DR   PDBsum; 1BJC; -.
DR   PDBsum; 1BRC; -.
DR   PDBsum; 1CA0; -.
DR   PDBsum; 1HZ3; -.
DR   PDBsum; 1IYT; -.
DR   PDBsum; 1MWP; -.
DR   PDBsum; 1OWT; -.
DR   PDBsum; 1QCM; -.
DR   PDBsum; 1QWP; -.
DR   PDBsum; 1QXC; -.
DR   PDBsum; 1QYT; -.
DR   PDBsum; 1TAW; -.
DR   PDBsum; 1TKN; -.
DR   PDBsum; 1UO7; -.
DR   PDBsum; 1UO8; -.
DR   PDBsum; 1UOA; -.
DR   PDBsum; 1UOI; -.
DR   PDBsum; 1X11; -.
DR   PDBsum; 1Z0Q; -.
DR   PDBsum; 1ZE7; -.
DR   PDBsum; 1ZE9; -.
DR   PDBsum; 1ZJD; -.
DR   PDBsum; 2BEG; -.
DR   PDBsum; 2BOM; -.
DR   PDBsum; 2BP4; -.
DR   PDBsum; 2FJZ; -.
DR   PDBsum; 2FK1; -.
DR   PDBsum; 2FK2; -.
DR   PDBsum; 2FK3; -.
DR   PDBsum; 2FKL; -.
DR   PDBsum; 2FMA; -.
DR   PDBsum; 2G47; -.
DR   PDBsum; 2IPU; -.
DR   PDBsum; 2LFM; -.
DR   PDBsum; 2LLM; -.
DR   PDBsum; 2LMN; -.
DR   PDBsum; 2LMO; -.
DR   PDBsum; 2LMP; -.
DR   PDBsum; 2LMQ; -.
DR   PDBsum; 2LNQ; -.
DR   PDBsum; 2LOH; -.
DR   PDBsum; 2LP1; -.
DR   PDBsum; 2LZ3; -.
DR   PDBsum; 2LZ4; -.
DR   PDBsum; 2M4J; -.
DR   PDBsum; 2M9R; -.
DR   PDBsum; 2M9S; -.
DR   PDBsum; 2MGT; -.
DR   PDBsum; 2MJ1; -.
DR   PDBsum; 2MPZ; -.
DR   PDBsum; 2MVX; -.
DR   PDBsum; 2MXU; -.
DR   PDBsum; 2NAO; -.
DR   PDBsum; 2OTK; -.
DR   PDBsum; 2R0W; -.
DR   PDBsum; 2WK3; -.
DR   PDBsum; 2Y29; -.
DR   PDBsum; 2Y2A; -.
DR   PDBsum; 2Y3J; -.
DR   PDBsum; 2Y3K; -.
DR   PDBsum; 2Y3L; -.
DR   PDBsum; 3AYU; -.
DR   PDBsum; 3BAE; -.
DR   PDBsum; 3BKJ; -.
DR   PDBsum; 3DXC; -.
DR   PDBsum; 3DXD; -.
DR   PDBsum; 3DXE; -.
DR   PDBsum; 3GCI; -.
DR   PDBsum; 3IFL; -.
DR   PDBsum; 3IFN; -.
DR   PDBsum; 3IFO; -.
DR   PDBsum; 3IFP; -.
DR   PDBsum; 3JQ5; -.
DR   PDBsum; 3JQL; -.
DR   PDBsum; 3JTI; -.
DR   PDBsum; 3KTM; -.
DR   PDBsum; 3L33; -.
DR   PDBsum; 3L81; -.
DR   PDBsum; 3MOQ; -.
DR   PDBsum; 3MXC; -.
DR   PDBsum; 3MXY; -.
DR   PDBsum; 3NYJ; -.
DR   PDBsum; 3NYL; -.
DR   PDBsum; 3OVJ; -.
DR   PDBsum; 3OW9; -.
DR   PDBsum; 3PZZ; -.
DR   PDBsum; 3Q2X; -.
DR   PDBsum; 3SV1; -.
DR   PDBsum; 3U0T; -.
DR   PDBsum; 3UMH; -.
DR   PDBsum; 3UMI; -.
DR   PDBsum; 3UMK; -.
DR   PDBsum; 4HIX; -.
DR   PDBsum; 4JFN; -.
DR   PDBsum; 4M1C; -.
DR   PDBsum; 4MDR; -.
DR   PDBsum; 4MVI; -.
DR   PDBsum; 4MVK; -.
DR   PDBsum; 4MVL; -.
DR   PDBsum; 4NGE; -.
DR   PDBsum; 4OJF; -.
DR   PDBsum; 4ONF; -.
DR   PDBsum; 4ONG; -.
DR   PDBsum; 4PQD; -.
DR   PDBsum; 4PWQ; -.
DR   PDBsum; 4XXD; -.
DR   PDBsum; 5AEF; -.
DR   PDBsum; 5AM8; -.
DR   PDBsum; 5AMB; -.
DR   PDBsum; 5BUO; -.
DR   PDBsum; 5C67; -.
DR   PDBsum; 5CSZ; -.
DR   PDBsum; 5HOW; -.
DR   PDBsum; 5HOX; -.
DR   PDBsum; 5HOY; -.
DR   PDBsum; 5KK3; -.
DR   PDBsum; 5LFY; -.
DR   PDBsum; 5LV0; -.
DR   PDBsum; 5MY4; -.
DR   PDBsum; 5MYO; -.
DR   PDBsum; 5MYX; -.
DR   PDBsum; 5ONP; -.
DR   PDBsum; 5ONQ; -.
DR   PDBsum; 5OQV; -.
DR   PDBsum; 5TXD; -.
DR   PDBsum; 5VOS; -.
DR   PDBsum; 5VZY; -.
DR   PDBsum; 5W3P; -.
DR   PDBsum; 6CO3; -.
DR   PDBsum; 6GFI; -.
DR   ProteinModelPortal; P05067; -.
DR   SMR; P05067; -.
DR   BioGrid; 106848; 2117.
DR   ComplexPortal; CPX-1062; Amyloid-beta protein 40/42 complex.
DR   ComplexPortal; CPX-1069; Amyloid-beta protein 40 complex.
DR   ComplexPortal; CPX-1070; Amyloid-beta protein 42 complex.
DR   ComplexPortal; CPX-1120; Amyloid-beta protein 40/42 oligomeric complex.
DR   ComplexPortal; CPX-1134; Amyloid-beta protein 42 oligomeric complex.
DR   ComplexPortal; CPX-1180; Amyloid-beta protein 40 oligomeric complex.
DR   CORUM; P05067; -.
DR   DIP; DIP-574N; -.
DR   ELM; P05067; -.
DR   IntAct; P05067; 193.
DR   MINT; P05067; -.
DR   STRING; 9606.ENSP00000284981; -.
DR   BindingDB; P05067; -.
DR   ChEMBL; CHEMBL2487; -.
DR   DrugBank; DB05150; CAD106.
DR   DrugBank; DB09148; Florbetaben (18F).
DR   DrugBank; DB09149; Florbetapir (18F).
DR   DrugBank; DB09151; Flutemetamol (18F).
DR   DrugBank; DB02235; L-methionine (R)-S-oxide.
DR   DrugBank; DB05846; Mito-4509.
DR   MEROPS; I02.015; -.
DR   TCDB; 1.C.50.1.2; the amyloid Beta-protein peptide (aBetapp) family.
DR   GlyConnect; 49; -.
DR   iPTMnet; P05067; -.
DR   PhosphoSitePlus; P05067; -.
DR   SwissPalm; P05067; -.
DR   UniCarbKB; P05067; -.
DR   BioMuta; APP; -.
DR   DMDM; 112927; -.
DR   SWISS-2DPAGE; P05067; -.
DR   EPD; P05067; -.
DR   jPOST; P05067; -.
DR   MaxQB; P05067; -.
DR   PaxDb; P05067; -.
DR   PeptideAtlas; P05067; -.
DR   PRIDE; P05067; -.
DR   ProteomicsDB; 51774; -.
DR   ProteomicsDB; 51775; -. [P05067-10]
DR   ProteomicsDB; 51776; -. [P05067-2]
DR   ProteomicsDB; 51777; -. [P05067-3]
DR   ProteomicsDB; 51778; -. [P05067-4]
DR   ProteomicsDB; 51779; -. [P05067-5]
DR   ProteomicsDB; 51780; -. [P05067-6]
DR   ProteomicsDB; 51781; -. [P05067-7]
DR   ProteomicsDB; 51782; -. [P05067-8]
DR   ProteomicsDB; 51783; -. [P05067-9]
DR   DNASU; 351; -.
DR   Ensembl; ENST00000346798; ENSP00000284981; ENSG00000142192. [P05067-1]
DR   Ensembl; ENST00000348990; ENSP00000345463; ENSG00000142192. [P05067-4]
DR   Ensembl; ENST00000354192; ENSP00000346129; ENSG00000142192. [P05067-10]
DR   Ensembl; ENST00000357903; ENSP00000350578; ENSG00000142192. [P05067-8]
DR   Ensembl; ENST00000358918; ENSP00000351796; ENSG00000142192. [P05067-9]
DR   Ensembl; ENST00000440126; ENSP00000387483; ENSG00000142192. [P05067-11]
DR   GeneID; 351; -.
DR   KEGG; hsa:351; -.
DR   UCSC; uc002ylz.4; human. [P05067-1]
DR   CTD; 351; -.
DR   DisGeNET; 351; -.
DR   EuPathDB; HostDB:ENSG00000142192.20; -.
DR   GeneCards; APP; -.
DR   HGNC; HGNC:620; APP.
DR   HPA; CAB000157; -.
DR   HPA; HPA001462; -.
DR   MalaCards; APP; -.
DR   MIM; 104300; phenotype.
DR   MIM; 104760; gene.
DR   MIM; 605714; phenotype.
DR   neXtProt; NX_P05067; -.
DR   OpenTargets; ENSG00000142192; -.
DR   Orphanet; 324723; ABeta amyloidosis, Arctic type.
DR   Orphanet; 100006; ABeta amyloidosis, Dutch type.
DR   Orphanet; 324708; ABeta amyloidosis, Iowa type.
DR   Orphanet; 324713; ABeta amyloidosis, Italian type.
DR   Orphanet; 324718; ABetaA21G amyloidosis.
DR   Orphanet; 324703; ABetaL34V amyloidosis.
DR   Orphanet; 1020; Early-onset autosomal dominant Alzheimer disease.
DR   PharmGKB; PA24910; -.
DR   eggNOG; KOG3540; Eukaryota.
DR   eggNOG; ENOG410ZW2A; LUCA.
DR   GeneTree; ENSGT00530000063252; -.
DR   HOGENOM; HOG000232190; -.
DR   HOVERGEN; HBG000051; -.
DR   InParanoid; P05067; -.
DR   KO; K04520; -.
DR   OMA; KQCKTHA; -.
DR   OrthoDB; 1010560at2759; -.
DR   PhylomeDB; P05067; -.
DR   TreeFam; TF317274; -.
DR   BioCyc; MetaCyc:ENSG00000142192-MONOMER; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-HSA-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-844456; The NLRP3 inflammasome.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SABIO-RK; P05067; -.
DR   SIGNOR; P05067; -.
DR   ChiTaRS; APP; human.
DR   EvolutionaryTrace; P05067; -.
DR   GeneWiki; Amyloid_precursor_protein; -.
DR   GenomeRNAi; 351; -.
DR   PMAP-CutDB; P05067; -.
DR   PRO; PR:P05067; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000142192; Expressed in 242 organ(s), highest expression level in frontal cortex.
DR   ExpressionAtlas; P05067; baseline and differential.
DR   Genevisible; P05067; HS.
DR   GO; GO:0106003; C:amyloid-beta complex; IMP:ARUK-UCL.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0097449; C:astrocyte projection; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0035253; C:ciliary rootlet; IEA:Ensembl.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043198; C:dendritic shaft; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0005769; C:early endosome; IDA:ARUK-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0031904; C:endosome lumen; TAS:ARUK-UCL.
DR   GO; GO:0070381; C:endosome to plasma membrane transport vesicle; IDA:ARUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:ARUK-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005798; C:Golgi-associated vesicle; ISS:UniProtKB.
DR   GO; GO:1990812; C:growth cone filopodium; IEA:Ensembl.
DR   GO; GO:1990761; C:growth cone lamellipodium; IEA:Ensembl.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0005622; C:intracellular; IDA:ARUK-UCL.
DR   GO; GO:1990777; C:lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0044304; C:main axon; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:ARUK-UCL.
DR   GO; GO:0045121; C:membrane raft; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:ARUK-UCL.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0005641; C:nuclear envelope lumen; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005634; C:nucleus; IGI:ARUK-UCL.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0048786; C:presynaptic active zone; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:ARUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0055037; C:recycling endosome; ISS:UniProtKB.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:GOC.
DR   GO; GO:0051233; C:spindle midzone; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030549; F:acetylcholine receptor activator activity; TAS:ARUK-UCL.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IPI:UniProtKB.
DR   GO; GO:0097645; F:amylin binding; TAS:ARUK-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:ARUK-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:ARUK-UCL.
DR   GO; GO:0042056; F:chemoattractant activity; IGI:ARUK-UCL.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0005109; F:frizzled binding; IPI:ARUK-UCL.
DR   GO; GO:0070851; F:growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:1904399; F:heparan sulfate binding; TAS:ARUK-UCL.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IMP:ARUK-UCL.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0005178; F:integrin binding; IDA:ARUK-UCL.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISS:ARUK-UCL.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:ARUK-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:ARUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:ARUK-UCL.
DR   GO; GO:0051425; F:PTB domain binding; IPI:BHF-UCL.
DR   GO; GO:0050786; F:RAGE receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0030546; F:receptor activator activity; IDA:ARUK-UCL.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IGI:ARUK-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0000187; P:activation of MAPK activity; ISS:ARUK-UCL.
DR   GO; GO:0000185; P:activation of MAPKKK activity; IGI:ARUK-UCL.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:UniProtKB.
DR   GO; GO:1990000; P:amyloid fibril formation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019732; P:antifungal humoral response; IMP:UniProtKB.
DR   GO; GO:0061844; P:antimicrobial humoral immune response mediated by antimicrobial peptide; IMP:UniProtKB.
DR   GO; GO:0008306; P:associative learning; IGI:ARUK-UCL.
DR   GO; GO:0048143; P:astrocyte activation; IGI:ARUK-UCL.
DR   GO; GO:0002265; P:astrocyte activation involved in immune response; IGI:ARUK-UCL.
DR   GO; GO:0008088; P:axo-dendritic transport; ISS:UniProtKB.
DR   GO; GO:0016199; P:axon midline choice point recognition; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:ARUK-UCL.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0009987; P:cellular process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:0071280; P:cellular response to copper ion; IEA:Ensembl.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071874; P:cellular response to norepinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0050890; P:cognition; ISS:UniProtKB.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; ISS:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0045087; P:innate immune response; IMP:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007612; P:learning; IMP:ARUK-UCL.
DR   GO; GO:0007611; P:learning or memory; IMP:ARUK-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IC:ARUK-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007617; P:mating behavior; ISS:UniProtKB.
DR   GO; GO:0046466; P:membrane lipid catabolic process; IDA:ARUK-UCL.
DR   GO; GO:0007613; P:memory; IGI:ARUK-UCL.
DR   GO; GO:0014005; P:microglia development; IGI:ARUK-UCL.
DR   GO; GO:0001774; P:microglial cell activation; IGI:ARUK-UCL.
DR   GO; GO:0090647; P:modulation of age-related behavioral decline; IMP:ARUK-UCL.
DR   GO; GO:0098815; P:modulation of excitatory postsynaptic potential; IGI:ARUK-UCL.
DR   GO; GO:0006378; P:mRNA polyadenylation; ISS:UniProtKB.
DR   GO; GO:1903523; P:negative regulation of blood circulation; IGI:ARUK-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:ARUK-UCL.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IGI:ARUK-UCL.
DR   GO; GO:0010823; P:negative regulation of mitochondrion organization; TAS:ARUK-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:ARUK-UCL.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:1902894; P:negative regulation of pri-miRNA transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:1900181; P:negative regulation of protein localization to nucleus; IGI:ARUK-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IGI:ARUK-UCL.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:1990535; P:neuron projection maintenance; IGI:ARUK-UCL.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0061903; P:positive regulation of 1-phosphatidylinositol-3-kinase activity; IGI:ARUK-UCL.
DR   GO; GO:1905908; P:positive regulation of amyloid fibril formation; IMP:ARUK-UCL.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; IGI:ARUK-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:ARUK-UCL.
DR   GO; GO:1902961; P:positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IGI:ARUK-UCL.
DR   GO; GO:0061890; P:positive regulation of astrocyte activation; IGI:ARUK-UCL.
DR   GO; GO:0050867; P:positive regulation of cell activation; NAS:ARUK-UCL.
DR   GO; GO:1905893; P:positive regulation of cellular response to thapsigargin; IDA:ARUK-UCL.
DR   GO; GO:1905896; P:positive regulation of cellular response to tunicamycin; IDA:ARUK-UCL.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; IGI:ARUK-UCL.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:ARUK-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; NAS:ARUK-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IGI:ARUK-UCL.
DR   GO; GO:1904472; P:positive regulation of endothelin secretion; IGI:ARUK-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IGI:ARUK-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IGI:ARUK-UCL.
DR   GO; GO:1904022; P:positive regulation of G protein-coupled receptor internalization; IDA:ARUK-UCL.
DR   GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IGI:ARUK-UCL.
DR   GO; GO:0050725; P:positive regulation of interleukin-1 beta biosynthetic process; IGI:ARUK-UCL.
DR   GO; GO:0045410; P:positive regulation of interleukin-6 biosynthetic process; IGI:ARUK-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IGI:ARUK-UCL.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IGI:ARUK-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IGI:ARUK-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:ARUK-UCL.
DR   GO; GO:1903980; P:positive regulation of microglial cell activation; IGI:ARUK-UCL.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:ARUK-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:ARUK-UCL.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:ARUK-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IGI:ARUK-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IGI:ARUK-UCL.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IDA:ARUK-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IGI:ARUK-UCL.
DR   GO; GO:1903223; P:positive regulation of oxidative stress-induced neuron death; IGI:ARUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ARUK-UCL.
DR   GO; GO:1904591; P:positive regulation of protein import; IDA:ARUK-UCL.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; NAS:ARUK-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; NAS:ARUK-UCL.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IMP:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IGI:ARUK-UCL.
DR   GO; GO:1900122; P:positive regulation of receptor binding; IDA:ARUK-UCL.
DR   GO; GO:1905898; P:positive regulation of response to endoplasmic reticulum stress; IDA:ARUK-UCL.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IGI:ARUK-UCL.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IMP:ARUK-UCL.
DR   GO; GO:1902949; P:positive regulation of tau-protein kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IGI:ARUK-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IGI:ARUK-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IMP:ARUK-UCL.
DR   GO; GO:0070206; P:protein trimerization; IMP:ARUK-UCL.
DR   GO; GO:1903048; P:regulation of acetylcholine-gated cation channel activity; IGI:ARUK-UCL.
DR   GO; GO:1905906; P:regulation of amyloid fibril formation; IGI:ARUK-UCL.
DR   GO; GO:1900221; P:regulation of amyloid-beta clearance; IC:ARUK-UCL.
DR   GO; GO:1902950; P:regulation of dendritic spine maintenance; IGI:ARUK-UCL.
DR   GO; GO:0007176; P:regulation of epidermal growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IGI:ARUK-UCL.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IGI:ARUK-UCL.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; TAS:ARUK-UCL.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:1905606; P:regulation of presynapse assembly; IDA:SynGO.
DR   GO; GO:1905945; P:regulation of response to calcium ion; ISS:ARUK-UCL.
DR   GO; GO:0150003; P:regulation of spontaneous synaptic transmission; IGI:ARUK-UCL.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; ISS:UniProtKB.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IGI:ARUK-UCL.
DR   GO; GO:0006417; P:regulation of translation; ISS:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; IC:ARUK-UCL.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0001878; P:response to yeast; IMP:UniProtKB.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   GO; GO:0050808; P:synapse organization; IGI:ARUK-UCL.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0032640; P:tumor necrosis factor production; IGI:ARUK-UCL.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   CDD; cd00109; KU; 1.
DR   Gene3D; 1.20.120.770; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.1490.140; -; 1.
DR   Gene3D; 3.90.570.10; -; 1.
DR   Gene3D; 4.10.230.10; -; 1.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR036669; Amyloid_Cu-bd_sf.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR037071; Amyloid_glyco_Abeta_sf.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR019744; Amyloid_glyco_extracell_CS.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR036454; Amyloid_glyco_heparin-bd_sf.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR028866; APP.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR036176; E2_sf.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR036880; Kunitz_BPTI_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103; PTHR23103; 1.
DR   PANTHER; PTHR23103:SF7; PTHR23103:SF7; 1.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF109843; SSF109843; 1.
DR   SUPFAM; SSF56491; SSF56491; 1.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   SUPFAM; SSF89811; SSF89811; 1.
DR   PROSITE; PS00319; APP_CUBD; 1.
DR   PROSITE; PS51869; APP_E1; 1.
DR   PROSITE; PS51870; APP_E2; 1.
DR   PROSITE; PS00320; APP_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Alzheimer disease; Amyloid;
KW   Amyloidosis; Apoptosis; Cell adhesion; Cell membrane; Cell projection;
KW   Coated pit; Complete proteome; Copper; Cytoplasm; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endocytosis; Endosome; Glycoprotein; Heparin-binding; Iron;
KW   Isopeptide bond; Membrane; Metal-binding; Neurodegeneration;
KW   Notch signaling pathway; Nucleus; Oxidation; Phosphoprotein;
KW   Polymorphism; Protease inhibitor; Proteoglycan; Reference proteome;
KW   Secreted; Serine protease inhibitor; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Zinc.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:2900137,
FT                                ECO:0000269|PubMed:3597385}.
FT   CHAIN        18    770       Amyloid-beta precursor protein.
FT                                /FTId=PRO_0000000088.
FT   CHAIN        18    687       Soluble APP-alpha.
FT                                /FTId=PRO_0000000089.
FT   CHAIN        18    671       Soluble APP-beta.
FT                                /FTId=PRO_0000000090.
FT   CHAIN        18    286       N-APP.
FT                                /FTId=PRO_0000381966.
FT   CHAIN       672    770       C99.
FT                                /FTId=PRO_0000000091.
FT   CHAIN       672    713       Amyloid-beta protein 42.
FT                                /FTId=PRO_0000000092.
FT   CHAIN       672    711       Amyloid-beta protein 40.
FT                                /FTId=PRO_0000000093.
FT   CHAIN       688    770       C83.
FT                                /FTId=PRO_0000000094.
FT   PEPTIDE     688    713       P3(42).
FT                                /FTId=PRO_0000000095.
FT   PEPTIDE     688    711       P3(40).
FT                                /FTId=PRO_0000000096.
FT   CHAIN       691    770       C80.
FT                                /FTId=PRO_0000384574.
FT   CHAIN       712    770       Gamma-secretase C-terminal fragment 59.
FT                                /FTId=PRO_0000000097.
FT   CHAIN       714    770       Gamma-secretase C-terminal fragment 57.
FT                                /FTId=PRO_0000000098.
FT   CHAIN       721    770       Gamma-secretase C-terminal fragment 50.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000000099.
FT   CHAIN       740    770       C31.
FT                                /FTId=PRO_0000000100.
FT   TOPO_DOM     18    701       Extracellular. {ECO:0000305}.
FT   TRANSMEM    702    722       Helical. {ECO:0000305|PubMed:22584060,
FT                                ECO:0000305|PubMed:22654059}.
FT   TOPO_DOM    723    770       Cytoplasmic. {ECO:0000305}.
FT   DOMAIN       28    189       E1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01217}.
FT   DOMAIN      291    341       BPTI/Kunitz inhibitor.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DOMAIN      374    565       E2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01218}.
FT   REGION       28    123       GFLD subdomain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01217}.
FT   REGION       96    110       Heparin-binding.
FT   REGION      131    189       CuBD subdomain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01217}.
FT   REGION      181    188       Zinc-binding.
FT   REGION      391    423       Heparin-binding.
FT   REGION      491    522       Heparin-binding.
FT   REGION      523    540       Collagen-binding.
FT                                {ECO:0000269|PubMed:8576160}.
FT   REGION      732    751       Interaction with G(o)-alpha.
FT   MOTIF       724    734       Basolateral sorting signal.
FT   MOTIF       757    762       YENPXY motif; contains endocytosis
FT                                signal. {ECO:0000269|PubMed:10383380}.
FT   COMPBIAS    230    260       Asp/Glu-rich (acidic).
FT   COMPBIAS    274    280       Poly-Thr.
FT   METAL       147    147       Copper 1. {ECO:0000244|PDB:2FK1,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:17239395,
FT                                ECO:0000269|PubMed:25122912}.
FT   METAL       151    151       Copper 1. {ECO:0000244|PDB:2FK1,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:17239395,
FT                                ECO:0000269|PubMed:25122912}.
FT   METAL       168    168       Copper 1. {ECO:0000244|PDB:2FK1,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:17239395}.
FT   METAL       677    677       Copper or zinc 2.
FT                                {ECO:0000269|PubMed:11274207,
FT                                ECO:0000269|PubMed:26898943}.
FT   METAL       681    681       Copper or zinc 2.
FT                                {ECO:0000305|PubMed:10413512,
FT                                ECO:0000305|PubMed:11274207}.
FT   METAL       684    684       Copper or zinc 2.
FT                                {ECO:0000269|PubMed:10413512,
FT                                ECO:0000269|PubMed:11274207,
FT                                ECO:0000269|PubMed:26898943}.
FT   METAL       685    685       Copper or zinc 2.
FT                                {ECO:0000269|PubMed:11274207,
FT                                ECO:0000269|PubMed:26898943}.
FT   SITE        170    170       Required for Cu(2+) reduction.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01217}.
FT   SITE        197    198       Cleavage; by caspases.
FT                                {ECO:0000269|PubMed:10319819}.
FT   SITE        219    220       Cleavage; by caspases.
FT                                {ECO:0000269|PubMed:10319819}.
FT   SITE        301    302       Reactive bond.
FT   SITE        671    672       Cleavage; by beta-secretase.
FT                                {ECO:0000305|PubMed:11851430}.
FT   SITE        672    673       Cleavage; by caspase-6; when associated
FT                                with variant 670-N-L-671.
FT   SITE        687    688       Cleavage; by alpha-secretase.
FT                                {ECO:0000305|PubMed:11851430}.
FT   SITE        690    691       Cleavage; by theta-secretase.
FT                                {ECO:0000269|PubMed:16816112}.
FT   SITE        704    704       Implicated in free radical propagation.
FT                                {ECO:0000250}.
FT   SITE        706    706       Susceptible to oxidation.
FT                                {ECO:0000269|PubMed:10535332}.
FT   SITE        711    712       Cleavage; by gamma-secretase; site 1.
FT                                {ECO:0000305|PubMed:11851430}.
FT   SITE        713    714       Cleavage; by gamma-secretase; site 2.
FT                                {ECO:0000305|PubMed:11851430}.
FT   SITE        720    721       Cleavage; by gamma-secretase; site 3.
FT                                {ECO:0000269|PubMed:11851430}.
FT   SITE        739    740       Cleavage; by caspase-6, caspase-8 or
FT                                caspase-9. {ECO:0000269|PubMed:10319819}.
FT   MOD_RES     198    198       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:8999878}.
FT   MOD_RES     206    206       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:8999878}.
FT   MOD_RES     441    441       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     497    497       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     729    729       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   MOD_RES     730    730       Phosphoserine; by APP-kinase I.
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   MOD_RES     743    743       Phosphothreonine; by CDK5 and MAPK10.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:8131745}.
FT   MOD_RES     757    757       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11877420}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000305}.
FT   CARBOHYD    633    633       O-linked (GalNAc...) threonine; partial.
FT                                {ECO:0000269|PubMed:21712440,
FT                                ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    651    651       O-linked (GalNAc...) threonine; partial.
FT                                {ECO:0000269|PubMed:21712440,
FT                                ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    652    652       O-linked (GalNAc...) threonine; partial.
FT                                {ECO:0000269|PubMed:21712440,
FT                                ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    656    656       O-linked (Xyl...) (chondroitin sulfate)
FT                                serine; in L-APP isoforms.
FT                                {ECO:0000269|PubMed:21712440}.
FT   CARBOHYD    659    659       O-linked (HexNAc...) threonine; partial.
FT                                {ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    663    663       O-linked (GalNAc...) threonine; partial.
FT                                {ECO:0000269|PubMed:22576872,
FT                                ECO:0000305|PubMed:21712440}.
FT   CARBOHYD    667    667       O-linked (GalNAc...) serine; partial.
FT                                {ECO:0000269|PubMed:22576872,
FT                                ECO:0000305|PubMed:21712440}.
FT   CARBOHYD    681    681       O-linked (HexNAc...) tyrosine; partial.
FT                                {ECO:0000269|PubMed:22576872}.
FT   DISULFID     38     62       {ECO:0000244|PDB:1MWP,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4JFN,
FT                                ECO:0000244|PDB:4PQD,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217}.
FT   DISULFID     73    117       {ECO:0000244|PDB:1MWP,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4JFN,
FT                                ECO:0000244|PDB:4PQD,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217}.
FT   DISULFID     98    105       {ECO:0000244|PDB:1MWP,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4PQD,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217}.
FT   DISULFID    133    187       {ECO:0000244|PDB:1OWT,
FT                                ECO:0000244|PDB:2FJZ,
FT                                ECO:0000244|PDB:2FK1,
FT                                ECO:0000244|PDB:2FK2,
FT                                ECO:0000244|PDB:2FK3,
FT                                ECO:0000244|PDB:2FKL,
FT                                ECO:0000244|PDB:2FMA,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:12611883,
FT                                ECO:0000269|PubMed:17239395,
FT                                ECO:0000269|PubMed:17909280}.
FT   DISULFID    144    174       {ECO:0000244|PDB:1OWT,
FT                                ECO:0000244|PDB:2FJZ,
FT                                ECO:0000244|PDB:2FK1,
FT                                ECO:0000244|PDB:2FK2,
FT                                ECO:0000244|PDB:2FK3,
FT                                ECO:0000244|PDB:2FKL,
FT                                ECO:0000244|PDB:2FMA,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:12611883,
FT                                ECO:0000269|PubMed:17239395,
FT                                ECO:0000269|PubMed:17909280}.
FT   DISULFID    158    186       {ECO:0000244|PDB:1OWT,
FT                                ECO:0000244|PDB:2FJZ,
FT                                ECO:0000244|PDB:2FK1,
FT                                ECO:0000244|PDB:2FK2,
FT                                ECO:0000244|PDB:2FK3,
FT                                ECO:0000244|PDB:2FKL,
FT                                ECO:0000244|PDB:2FMA,
FT                                ECO:0000244|PDB:3KTM,
FT                                ECO:0000244|PDB:4PWQ,
FT                                ECO:0000255|PROSITE-ProRule:PRU01217,
FT                                ECO:0000269|PubMed:12611883,
FT                                ECO:0000269|PubMed:17239395,
FT                                ECO:0000269|PubMed:17909280}.
FT   DISULFID    291    341       {ECO:0000244|PDB:1AAP,
FT                                ECO:0000244|PDB:1BRC,
FT                                ECO:0000244|PDB:1CA0,
FT                                ECO:0000244|PDB:1TAW,
FT                                ECO:0000244|PDB:1ZJD,
FT                                ECO:0000244|PDB:3L33}.
FT   DISULFID    300    324       {ECO:0000244|PDB:1AAP,
FT                                ECO:0000244|PDB:1BRC,
FT                                ECO:0000244|PDB:1CA0,
FT                                ECO:0000244|PDB:1TAW,
FT                                ECO:0000244|PDB:1ZJD,
FT                                ECO:0000244|PDB:3L33,
FT                                ECO:0000244|PDB:5C67}.
FT   DISULFID    316    337       {ECO:0000244|PDB:1AAP,
FT                                ECO:0000244|PDB:1BRC,
FT                                ECO:0000244|PDB:1CA0,
FT                                ECO:0000244|PDB:1TAW,
FT                                ECO:0000244|PDB:1ZJD,
FT                                ECO:0000244|PDB:3L33,
FT                                ECO:0000244|PDB:5C67}.
FT   CROSSLNK    763    763       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   VAR_SEQ       1     19       MLPGLALLLLAAWTARALE -> MDQLEDLLVLFINY (in
FT                                isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045446.
FT   VAR_SEQ      19     74       Missing (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009116.
FT   VAR_SEQ     289    363       Missing (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009117.
FT   VAR_SEQ     289    289       E -> V (in isoform APP695, isoform L-
FT                                APP696, isoform L-APP677 and isoform
FT                                APP714). {ECO:0000303|PubMed:2881207}.
FT                                /FTId=VSP_000002.
FT   VAR_SEQ     290    364       Missing (in isoform APP695 and isoform L-
FT                                APP677). {ECO:0000303|PubMed:2881207}.
FT                                /FTId=VSP_000004.
FT   VAR_SEQ     290    345       Missing (in isoform L-APP696 and isoform
FT                                APP714). {ECO:0000305}.
FT                                /FTId=VSP_000003.
FT   VAR_SEQ     290    305       VCSEQAETGPCRAMIS -> KWYKEVHSGQARWLML (in
FT                                isoform APP305).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000005.
FT   VAR_SEQ     306    770       Missing (in isoform APP305).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000006.
FT   VAR_SEQ     345    364       MSQSLLKTTQEPLARDPVKL -> I (in isoform
FT                                11). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045447.
FT   VAR_SEQ     345    345       M -> I (in isoform L-APP733 and isoform
FT                                APP751). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1587857,
FT                                ECO:0000303|PubMed:2893289}.
FT                                /FTId=VSP_000007.
FT   VAR_SEQ     346    364       Missing (in isoform L-APP733 and isoform
FT                                APP751). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1587857,
FT                                ECO:0000303|PubMed:2893289}.
FT                                /FTId=VSP_000008.
FT   VAR_SEQ     364    364       L -> V (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009118.
FT   VAR_SEQ     637    654       Missing (in isoform L-APP677, isoform L-
FT                                APP696, isoform L-APP733 and isoform L-
FT                                APP752). {ECO:0000303|PubMed:1587857}.
FT                                /FTId=VSP_000009.
FT   VARIANT     501    501       E -> K (in dbSNP:rs45588932).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_022315.
FT   VARIANT     665    665       E -> D (in a patient with late onset
FT                                Alzheimer disease; dbSNP:rs63750363).
FT                                {ECO:0000269|PubMed:8154870}.
FT                                /FTId=VAR_010107.
FT   VARIANT     670    671       KM -> NL (in AD1; Swedish mutation;
FT                                highly increases hydrolysis by BACE1 and
FT                                amyloid-beta proteins production;
FT                                dbSNP:rs281865161).
FT                                {ECO:0000269|PubMed:10656250,
FT                                ECO:0000269|PubMed:10677483,
FT                                ECO:0000269|PubMed:1302033,
FT                                ECO:0000269|PubMed:1465129}.
FT                                /FTId=VAR_000015.
FT   VARIANT     678    678       D -> N (in AD1; dbSNP:rs63750064).
FT                                {ECO:0000269|PubMed:15201367}.
FT                                /FTId=VAR_044424.
FT   VARIANT     692    692       A -> G (in AD1; Flemish mutation;
FT                                increases the solubility of processed
FT                                amyloid-beta peptides and increases the
FT                                stability of peptide oligomers;
FT                                dbSNP:rs63750671).
FT                                {ECO:0000269|PubMed:11311152,
FT                                ECO:0000269|PubMed:1303239,
FT                                ECO:0000269|PubMed:9754958}.
FT                                /FTId=VAR_000016.
FT   VARIANT     693    693       E -> G (in AD1; dbSNP:rs63751039).
FT                                {ECO:0000269|PubMed:11528419,
FT                                ECO:0000269|PubMed:1415269}.
FT                                /FTId=VAR_014215.
FT   VARIANT     693    693       E -> K (in CAA-APP; Italian type;
FT                                dbSNP:rs63750579).
FT                                {ECO:0000269|PubMed:20697050}.
FT                                /FTId=VAR_014216.
FT   VARIANT     693    693       E -> Q (in CAA-APP; Dutch type;
FT                                dbSNP:rs63750579).
FT                                {ECO:0000269|PubMed:2111584}.
FT                                /FTId=VAR_000017.
FT   VARIANT     694    694       D -> N (in CAA-APP; Iowa type;
FT                                dbSNP:rs63749810).
FT                                {ECO:0000269|PubMed:11409420,
FT                                ECO:0000269|PubMed:12654973}.
FT                                /FTId=VAR_014217.
FT   VARIANT     705    705       L -> V (in CAA-APP; Italian type;
FT                                dbSNP:rs63750921).
FT                                {ECO:0000269|PubMed:16178030}.
FT                                /FTId=VAR_032276.
FT   VARIANT     713    713       A -> T (in AD1; dbSNP:rs63750066).
FT                                {ECO:0000269|PubMed:1303275,
FT                                ECO:0000269|PubMed:15365148}.
FT                                /FTId=VAR_000019.
FT   VARIANT     713    713       A -> V (in one chronic schizophrenia
FT                                patient; unknown pathological
FT                                significance; dbSNP:rs1800557).
FT                                {ECO:0000269|PubMed:1307241}.
FT                                /FTId=VAR_000018.
FT   VARIANT     714    714       T -> A (in AD1; dbSNP:rs63750643).
FT                                {ECO:0000269|PubMed:12034808}.
FT                                /FTId=VAR_032277.
FT   VARIANT     714    714       T -> I (in AD1; increased amyloid-beta
FT                                protein 42/40 ratio; dbSNP:rs63750973).
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:15668448}.
FT                                /FTId=VAR_014218.
FT   VARIANT     715    715       V -> M (in AD1; decreased amyloid-beta
FT                                protein 40/total amyloid-beta;
FT                                dbSNP:rs63750734).
FT                                {ECO:0000269|PubMed:10097173}.
FT                                /FTId=VAR_010108.
FT   VARIANT     716    716       I -> V (in AD1; dbSNP:rs63750399).
FT                                {ECO:0000269|PubMed:9328472}.
FT                                /FTId=VAR_000020.
FT   VARIANT     717    717       V -> F (in AD1; increased amyloid-beta
FT                                protein 42/40 ratio; dbSNP:rs63750264).
FT                                {ECO:0000269|PubMed:1925564,
FT                                ECO:0000269|PubMed:8267572,
FT                                ECO:0000269|PubMed:8290042,
FT                                ECO:0000269|PubMed:8476439,
FT                                ECO:0000269|PubMed:8886002}.
FT                                /FTId=VAR_000023.
FT   VARIANT     717    717       V -> G (in AD1; increased amyloid-beta
FT                                protein 42/40 ratio; dbSNP:rs63749964).
FT                                {ECO:0000269|PubMed:1944558,
FT                                ECO:0000269|PubMed:8476439,
FT                                ECO:0000269|PubMed:8886002}.
FT                                /FTId=VAR_000022.
FT   VARIANT     717    717       V -> I (in AD1; increased amyloid-beta
FT                                protein 42/40 ratio; dbSNP:rs63750264).
FT                                {ECO:0000269|PubMed:10631141,
FT                                ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:1671712,
FT                                ECO:0000269|PubMed:1678058,
FT                                ECO:0000269|PubMed:1908231,
FT                                ECO:0000269|PubMed:8267572,
FT                                ECO:0000269|PubMed:8476439,
FT                                ECO:0000269|PubMed:8577393,
FT                                ECO:0000269|PubMed:8886002}.
FT                                /FTId=VAR_000021.
FT   VARIANT     717    717       V -> L (in AD1; dbSNP:rs63750264).
FT                                {ECO:0000269|PubMed:10867787}.
FT                                /FTId=VAR_014219.
FT   VARIANT     723    723       L -> P (in AD1; dbSNP:rs63751122).
FT                                {ECO:0000269|PubMed:10665499}.
FT                                /FTId=VAR_010109.
FT   MUTAGEN      99    102       KRGR->NQGG: Reduced heparin-binding.
FT                                {ECO:0000269|PubMed:8158260}.
FT   MUTAGEN     108    108       H->A: Loss of the copper binding site in
FT                                the GFLD subdomain; when associated with
FT                                A-110. {ECO:0000269|PubMed:25122912}.
FT   MUTAGEN     110    110       H->A: Loss of the copper binding site in
FT                                the GFLD subdomain; when associated with
FT                                A-108. {ECO:0000269|PubMed:25122912}.
FT   MUTAGEN     137    137       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     141    141       M->T: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     144    144       C->S: Binds copper. No dimer formation.
FT                                No copper reducing activity.
FT                                {ECO:0000269|PubMed:10461923,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    149       HLH->ALA: 50% decrease in copper reducing
FT                                activity. {ECO:0000269|PubMed:10461923}.
FT   MUTAGEN     147    147       H->A: Loss of a copper binding site; when
FT                                associated with A-151.
FT                                {ECO:0000269|PubMed:25122912}.
FT   MUTAGEN     147    147       H->A: Some decrease in copper reducing
FT                                activity. {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    147       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    147       H->Y: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     151    151       H->A: Loss of a copper binding site; when
FT                                associated with A-147.
FT                                {ECO:0000269|PubMed:25122912}.
FT   MUTAGEN     151    151       H->K: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     151    151       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     198    198       S->A: Greatly reduced casein kinase
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:10806211,
FT                                ECO:0000269|PubMed:8999878}.
FT   MUTAGEN     206    206       S->A: Reduced casein kinase
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:10806211,
FT                                ECO:0000269|PubMed:8999878}.
FT   MUTAGEN     499    499       R->A: Reduced affinity for heparin; when
FT                                associated with A-503.
FT                                {ECO:0000269|PubMed:15304215}.
FT   MUTAGEN     503    503       K->A: Reduced affinity for heparin; when
FT                                associated with A-499.
FT                                {ECO:0000269|PubMed:15304215}.
FT   MUTAGEN     656    656       S->A: Abolishes chondroitin sulfate
FT                                binding in L-APP733 isoform.
FT                                {ECO:0000269|PubMed:7737970}.
FT   MUTAGEN     676    676       R->G: 60-70% zinc-induced amyloid-beta
FT                                protein 28 aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     681    681       Y->F: 60-70% zinc-induced amyloid-beta
FT                                protein 28 aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     684    684       H->R: Only 23% zinc-induced amyloid-beta
FT                                protein 28 aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     704    704       G->V: Reduced protein oxidation. No
FT                                hippocampal neuron toxicity.
FT   MUTAGEN     706    706       M->L: Reduced lipid peroxidation
FT                                inhibition. {ECO:0000269|PubMed:10535332,
FT                                ECO:0000269|PubMed:9168929}.
FT   MUTAGEN     706    706       M->V: No free radical production. No
FT                                hippocampal neuron toxicity.
FT                                {ECO:0000269|PubMed:10535332,
FT                                ECO:0000269|PubMed:9168929}.
FT   MUTAGEN     717    717       V->C,S: Unchanged amyloid-beta protein
FT                                42/total amyloid-beta ratio.
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     717    717       V->K: Decreased amyloid-beta protein
FT                                42/total amyloid-beta ratio.
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     717    717       V->M: Increased amyloid-beta protein
FT                                42/40 ratio. No change in apoptosis after
FT                                caspase cleavage.
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     728    728       Y->A: No effect on APBA1 nor APBB1
FT                                binding. Greatly reduces the binding to
FT                                APPBP2. APP internalization unchanged. No
FT                                change in amyloid-beta protein 42
FT                                secretion. {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653,
FT                                ECO:0000269|PubMed:9843960}.
FT   MUTAGEN     739    739       D->A: No cleavage by caspases during
FT                                apoptosis. {ECO:0000269|PubMed:10319819,
FT                                ECO:0000269|PubMed:10742146,
FT                                ECO:0000269|PubMed:12214090}.
FT   MUTAGEN     739    739       D->N: No effect on FADD-induced
FT                                apoptosis. {ECO:0000269|PubMed:10319819,
FT                                ECO:0000269|PubMed:10742146,
FT                                ECO:0000269|PubMed:12214090}.
FT   MUTAGEN     743    743       T->A: Greatly reduces the binding to SHC1
FT                                and APBB family members; no effect on
FT                                NGF-stimulated neurite extension.
FT                                {ECO:0000269|PubMed:10341243,
FT                                ECO:0000269|PubMed:11146006,
FT                                ECO:0000269|PubMed:11517218,
FT                                ECO:0000269|PubMed:11877420}.
FT   MUTAGEN     743    743       T->E: Reduced NGF-stimulated neurite
FT                                extension. No effect on APP maturation.
FT                                {ECO:0000269|PubMed:10341243,
FT                                ECO:0000269|PubMed:11146006,
FT                                ECO:0000269|PubMed:11517218,
FT                                ECO:0000269|PubMed:11877420}.
FT   MUTAGEN     756    756       G->A: APP internalization unchanged. No
FT                                change in amyloid-beta protein 42
FT                                secretion. {ECO:0000269|PubMed:10383380}.
FT   MUTAGEN     757    757       Y->A: Little APP internalization. Reduced
FT                                amyloid-beta protein 42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:11724784,
FT                                ECO:0000269|PubMed:11877420,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     757    757       Y->G: Loss of binding to MAPK8IP1, APBA1,
FT                                APBB1, APPBP2 and SHC1.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:11724784,
FT                                ECO:0000269|PubMed:11877420,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     759    759       N->A: No binding to APBA1, no effect on
FT                                APBB1 binding. Little APP
FT                                internalization. Reduced amyloid-beta
FT                                protein 42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     760    760       P->A: Little APP internalization. Reduced
FT                                amyloid-beta protein 42 secretion.
FT                                {ECO:0000269|PubMed:10383380}.
FT   MUTAGEN     762    762       Y->A: Loss of binding to APBA1 and APBB1.
FT                                APP internalization unchanged. No change
FT                                in amyloid-beta protein 42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653}.
FT   CONFLICT     15     16       AR -> VW (in Ref. 3; CAA31830).
FT                                {ECO:0000305}.
FT   CONFLICT    647    647       D -> E (in Ref. 36; AAA51722).
FT                                {ECO:0000305}.
FT   CONFLICT    724    724       Missing (in Ref. 23; AAB26263/AAB26264).
FT                                {ECO:0000305}.
FT   CONFLICT    731    731       I -> N (in Ref. 23; AAB26263/AAB26264/
FT                                AAB26265). {ECO:0000305}.
FT   CONFLICT    757    757       Y -> S (in Ref. 31; AAA35540).
FT                                {ECO:0000305}.
FT   HELIX        26     28       {ECO:0000244|PDB:4PQD}.
FT   STRAND       33     35       {ECO:0000244|PDB:4PQD}.
FT   STRAND       43     45       {ECO:0000244|PDB:4PQD}.
FT   TURN         47     49       {ECO:0000244|PDB:4PQD}.
FT   STRAND       52     54       {ECO:0000244|PDB:4PQD}.
FT   STRAND       56     58       {ECO:0000244|PDB:4PWQ}.
FT   HELIX        66     76       {ECO:0000244|PDB:4PQD}.
FT   STRAND       82     87       {ECO:0000244|PDB:4PQD}.
FT   STRAND       92     94       {ECO:0000244|PDB:4PQD}.
FT   STRAND       97     99       {ECO:0000244|PDB:4PQD}.
FT   TURN        100    102       {ECO:0000244|PDB:4PQD}.
FT   STRAND      103    106       {ECO:0000244|PDB:4PQD}.
FT   STRAND      110    112       {ECO:0000244|PDB:4PQD}.
FT   STRAND      115    119       {ECO:0000244|PDB:4PQD}.
FT   STRAND      134    139       {ECO:0000244|PDB:2FMA}.
FT   HELIX       147    160       {ECO:0000244|PDB:2FMA}.
FT   STRAND      163    174       {ECO:0000244|PDB:2FMA}.
FT   TURN        175    177       {ECO:0000244|PDB:2FMA}.
FT   STRAND      178    188       {ECO:0000244|PDB:2FMA}.
FT   HELIX       288    292       {ECO:0000244|PDB:1AAP}.
FT   STRAND      299    301       {ECO:0000244|PDB:1AAP}.
FT   STRAND      304    310       {ECO:0000244|PDB:1AAP}.
FT   TURN        311    314       {ECO:0000244|PDB:1AAP}.
FT   STRAND      315    321       {ECO:0000244|PDB:1AAP}.
FT   STRAND      323    325       {ECO:0000244|PDB:1AAP}.
FT   STRAND      331    333       {ECO:0000244|PDB:1AAP}.
FT   HELIX       334    341       {ECO:0000244|PDB:1AAP}.
FT   HELIX       374    380       {ECO:0000244|PDB:3NYL}.
FT   HELIX       389    418       {ECO:0000244|PDB:3UMH}.
FT   STRAND      421    423       {ECO:0000244|PDB:3UMH}.
FT   HELIX       425    480       {ECO:0000244|PDB:3UMH}.
FT   STRAND      482    484       {ECO:0000244|PDB:3NYJ}.
FT   HELIX       487    518       {ECO:0000244|PDB:3UMH}.
FT   HELIX       520    546       {ECO:0000244|PDB:3UMH}.
FT   HELIX       547    550       {ECO:0000244|PDB:3UMH}.
FT   HELIX       552    566       {ECO:0000244|PDB:3UMH}.
FT   HELIX       615    618       {ECO:0000244|PDB:5BUO}.
FT   STRAND      620    622       {ECO:0000244|PDB:5BUO}.
FT   HELIX       673    675       {ECO:0000244|PDB:4OJF}.
FT   TURN        677    680       {ECO:0000244|PDB:5MYO}.
FT   STRAND      683    685       {ECO:0000244|PDB:1BA4}.
FT   STRAND      688    691       {ECO:0000244|PDB:3OVJ}.
FT   STRAND      692    694       {ECO:0000244|PDB:4MVI}.
FT   TURN        695    698       {ECO:0000244|PDB:4MVI}.
FT   STRAND      701    703       {ECO:0000244|PDB:3PZZ}.
FT   STRAND      707    712       {ECO:0000244|PDB:2Y3K}.
FT   HELIX       744    754       {ECO:0000244|PDB:3DXE}.
FT   STRAND      755    758       {ECO:0000244|PDB:1X11}.
FT   STRAND      763    765       {ECO:0000244|PDB:3L81}.
SQ   SEQUENCE   770 AA;  86943 MW;  A12EE761403740F5 CRC64;
     MLPGLALLLL AAWTARALEV PTDGNAGLLA EPQIAMFCGR LNMHMNVQNG KWDSDPSGTK
     TCIDTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHPH FVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDNVDSAD AEEDDSDVWW GGADTDYADG SEDKVVEVAE EEEVAEVEEE
     EADDDEDDED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSAMSQSLL KTTQEPLARD
     PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPRHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHSFGADSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
